Replication of the TRITON-TIMI Antiplatelet Trial in Healthcare Claims Data
Conditions: Antiplatelet
Sponsor: Brigham and Women's Hospital

Replication of Prasugrel versus Clopidogrel in Patients with Acute 
Coronary Syndromes (TRITON-TIMI 38 Trial)
January 13, 2020

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
1 
 
1. RCT Details 
This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely 
as possible given the remaining limitations inherent in the healthcare databases.  
 
1.1 Title 
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes (TRITON–TIMI 38 trial) 
 
1.2 Intended aim(s) 
 
To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-
high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg 
loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance 
dose), for 6 to 15 months. 
 
1.3 Primary endpoint for replication and RCT finding 
 
The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The 
key safety end point was major bleeding. 
 
1.4 Required power for primary endpoint and noninferiority margin (if applicable) 
 
We calculated that a total of 875 primary end points would be required for the study to have a 90% power to detect a 20% 
reduction in the relative risk of the primary end point among patients with unstable angina or non–ST-elevation myocardial 
infarction receiving prasugrel, as compared with clopidogrel. 
 
1.5 Primary trial estimate targeted for replication 
HR = 0.81 (95% CI 0.73–0.90) comparing prasugrel to clopidogrel (Wiviott et al., 2007) 
 
2. Person responsible for implementation of replication in Aetion 
Ajinkya Pawar, Ph.D. implemented the study design in the Aetion Evidence Platform. S/he is not responsible for the validity of the 
design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.   
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
2 
3. Data Source(s) 
United/Optum, MarketScan 
 
4. Study Design Diagram 
The study design diagram visualizes key aspects of the longitudinal study design for expedited review. 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
3 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
4 
 
5. Cohort Identification  
 
5.1 Cohort Summary 
This study will involve a new user, parallel group, cohort study design comparing prasugrel 90mg to clopidogrel 75mg. The 
patients will be required to have continuous enrollment during the baseline period of 180 days before initiation of prasugrel 
90mg or a comparator drug (cohort entry date). Follow-up for the outcome (3P-MACE), begins the day after drug initiation.  
 
5.2 Important steps for cohort formation 
 New users (defined as no use in 180 days prior to index date) of an exposure and a comparator drug will be identified. 
 
5.2.1 Eligible cohort entry dates 
Market availability of prasugrel in the U.S. started on 2009-07-10.       
• For Marketscan: 2009-07-10 to 2017-12-31 (end of data availability).  
• For Optum: 2009-07-10 to 2019-03-31 (end of data availability). 
 
5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date 
 
Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided 
in Appendix A and are summarized in the flowcharts below.   
 
5.3 Flowchart of the study cohort assembly 
 
 
Optum 
MarketScan 
 
Less Excluded 
Patients 
Remaining 
Patients 
Less Excluded 
Patients 
Remaining 
Patients 
All patients 
  
75,524,500 
  
191,990,035 
Patients meeting the cohort entry criteria of moderate to high risk Acute Coronary 
Syndrome undergoing PCI procedure  
-75219388 
305,112 
-191556394 
433,641 
Patients with sufficient enrollment period in the claims database 
-41910 
263,202 
-120017 
313,624 
Patients with moderate to high risk Acute Coronary Syndrome  
-144114 
119,088 
-165792 
147,832 
Patients initiating clopidogrel 75mg or prasugrel 10mg within 14 days of discharge of 
PCI hospitalization  
-56497 
62,591 
-54511 
93,321 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
5 
Patients without history of hemorrhagic stroke 
-349 
62,242 
-392 
92,929 
Patients without intracranial neoplasm, AV malformation, or aneurysm  
-186 
62,056 
-202 
92,727 
Patients without ischemic stroke occurring 90 days prior to PCI hospitalization  
-163 
61,893 
-255 
92,472 
Patients with sufficient claims enrollment after PCI hospital discharge  
-483 
61,410 
-1191 
91,281 
Parent: Final cohort 
  
61,410 
  
91,281 
Did not meet cohort entry criteria 
-80 
61,330 
0 
91,281 
Excluded due to insufficient enrollment 
0 
61,330 
0 
91,281 
Patients with no prior use of clopidogrel 
-3135 
58,195 
-3653 
87,628 
Patients with no prior use of prasugrel  
-535 
57,660 
-958 
86,670 
Patients without qualification in >1 exposure category 
-18 
57,642 
-20 
86,650 
Patients age 18 years or older  
-2 
57,640 
0 
86,650 
Patients without cardiogenic shock during PCI hospitalization  
-1811 
55,829 
-2457 
84,193 
Patients without refractory ventricular arrhythmias 
-5341 
50,488 
-7235 
76,958 
Patients without New York Heart Association Class IV congestive heart failure 
-416 
50,072 
-265 
76,693 
Patients without active internal bleeding or history of bleeding diathesis 
-3974 
46,098 
-3739 
72,954 
Patients without thrombocytopenia (platelet count of less than 100,000/mm3)  
0 
46,098 
0 
72,954 
Patients without anemia (hemoglobin <10 g/Dl)  
-886 
45,212 
-2039 
70,915 
Patients without a claim for thienopyridine 5 days or less before PCI hospitalization  
-1 
45,211 
-1 
70,914 
Patients without daily treatments with NSAIDs or COX-2 inhibitors  
-394 
44,817 
-654 
70,260 
Patients without concomitant medical illness that is potentially associated with 
reduced survival  
-687 
44,130 
-235 
70,025 
Patients without severe hepatic dysfunction  
-1755 
42,375 
-2041 
67,984 
Patients without issues on poor treatment compliance including alcoholism, mental 
illness, or drug dependence  
-2927 
39,448 
-1981 
66,003 
Final cohort 
  
39,448 
  
66,003 
 
 
6. Variables  
 
6.1 Exposure-related variables:  
 
Study drug:  
The study exposure of interest is initiation of Prasugrel. Initiation will be defined by no use of Prasugrel or a comparator in the prior 
6 months before treatment initiation (washout period).  
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
6 
Comparator agents: 
• Initiators of prasugrel 10mg will be compared to initiators of- 
o Clopidogrel 75mg 
 
6.2 Preliminary covariates: 
• Age 
• Sex 
• Combined Comorbidity Index (CCI), measured over the default baseline covariate assessment period, defined as 180 days 
prior to and including index date 
 
Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and analysis. 
We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between 
treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility 
analysis and the initial power assessment and are listed in Table 1 (Appendix B). 
 
6.3 Outcome variables and study follow-up:  
 
6.3.1 Outcome variables 
 
Effectiveness outcomes of interest (definitions provided in Appendix A):  
• Primary outcome: 3-point major adverse cardiovascular events (MACE), i.e., non-fatal myocardial infarction, non-fatal stroke, 
or CV mortality 
• Secondary outcomes: Individual components: 
o Hospital admission for MI (for purposes of this individual component, fatal MI is included) 
o Hospital admission for stroke (for purposes of this individual component, fatal stroke is included) 
o All-cause mortality/CV mortality: 
§ All-cause inpatient mortality identified using discharge status codes will be used as a proxy for “CV mortality” 
in Marketscan 
§ In Optum, all-cause inpatient mortality + all-cause mortality for Medicare Advantage patients is used 
 
Control outcome of interest (control outcome only serve to assess aspects of study validity but are not further interpreted):  

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
7 
1. Major bleeding (we expect to see increased risk with prasugrel; Wiviott, 2007) 
2. Pneumonia (we expect to see a null association) 
Control outcome definition 
Outcome 
Definition 
Comments 
Control Outcomes 
Major bleeding 
Any inpatient diagnosis of major bleeding -- code list provided in Appendix A  
Same code list used for both outcome 
and major bleed exclusion criteria 
Pneumonia 
Any inpatient diagnosis of pneumonia:    
  * 481 - PNEUMOCOCCAL PNEUMONIA [STREPTOCOCCUS PNEUMONIAE PNEUMONIA] 
  * 482 - OTHER BACTERIAL PNEUMONIA 
* 483 - PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM 
* 485 - BRONCHOPNEUMONIA ORGANISM UNSPECIFIED 
* 486 - PNEUMONIA ORGANISM UNSPECIFIED 
* 487.0 - INFLUENZA WITH PNEUMONIA 
* 507 - PNEUMONITIS DUE TO SOLIDS AND LIQUIDS 
* 482.0 - PNEUMONIA DUE TO KLEBSIELLA PNEUMONIAE 
* 482.1 - PNEUMONIA DUE TO PSEUDOMONAS 
* 482.2 - PNEUMONIA DUE TO HEMOPHILUS INFLUENZAE  
* 482.3 - PNEUMONIA DUE TO STREPTOCOCCUS 
* 482.30 - PNEUMONIA DUE TO STREPTOCOCCUS UNSPECIFIED 
* 482.31 - PNEUMONIA DUE TO STREPTOCOCCUS GROUP A 
* 482.32 - PNEUMONIA DUE TO STREPTOCOCCUS GROUP B 
* 482.39 - PNEUMONIA DUE TO OTHER STREPTOCOCCUS 
* 482.4 - PNEUMONIA DUE TO STAPHYLOCOCCUS 
* 482.40 - PNEUMONIA DUE TO STAPHYLOCOCCUS UNSPECIFIED 
* 482.41 - METHICILLIN SUSCEPTIBLE PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS 
* 482.42 - METHICILLIN RESISTANT PNEUMONIA DUE TO STAPHYLOCOCCUS AUREUS 
* 482.49 - OTHER STAPHYLOCOCCUS PNEUMONIA 
* 482.8 - PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
* 482.81 - PNEUMONIA DUE TO ANAEROBES 
* 482.82 - PNEUMONIA DUE TO ESCHERICHIA COLI [E.COLI] 
* 482.83 - PNEUMONIA DUE TO OTHER GRAM-NEGATIVE BACTERIA 
* 482.84 - PNEUMONIA DUE TO LEGIONNAIRES' DISEASE 
* 482.89 - PNEUMONIA DUE TO OTHER SPECIFIED BACTERIA 
* 482.9 - BACTERIAL PNEUMONIA UNSPECIFIED 
* 483.0 - PNEUMONIA DUE TO MYCOPLASMA PNEUMONIAE 
* 483.1 - PNEUMONIA DUE TO CHLAMYDIA 
* 483.8 - PNEUMONIA DUE TO OTHER SPECIFIED ORGANISM 
PPV = 85% (Aronsky, et al.; 2005); 
Note- The  corresponding ICD-10 
codes will also be used 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
8 
 
 
6.3.2 Study follow-up 
Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day of 
cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is the 
primary analysis, as it targets the relative hazard of outcomes on treatment.  
 
For the AT analyses, the follow-up will start the day after initiation of prasugrel and comparator and will continue until the earliest 
date of the following events: 
• The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,  
• The date of end of continuous registration in the database, 
• End of the study period, 
• Measured death event occurs, 
• Nursing home admission 
o Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to 
no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for 
cohorts for the same reason. 
• The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (prasugrel 
and comparator) plus a defined grace period (i.e., 30 days after the end of the last prescription’s days’ supply in main 
analyses). 
•  The date of augmentation or switching from an exposure to a comparator  
• Initiation of ticagrelor 
 
 
For the ITT analyses, the censoring based on the augmentation/switching and treatment discontinuation will be replaced with a 
maximum allowed follow-up time of 365 days.  
 
7. Initial Feasibility Analysis  
* 507.0 - PNEUMONITIS DUE TO INHALATION OF FOOD OR VOMITUS 
* 507.1 - PNEUMONITIS DUE TO INHALATION OF OILS AND ESSENCES 
* 507.8 - PNEUMONITIS DUE TO OTHER SOLIDS AND LIQUIDS 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
9 
 
Aetion report links: 
Optum: https://bwh-dope.aetion.com/projects/details/989/results/46156/result/0 
Marketscan: https://bwh-dope.aetion.com/projects/details/990/results/46157/result/0 
 
Date conducted: December 15, 2019 
 
Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the 
outcome. No measures of association will be computed nor will incidence rates stratified by treatment group. 
 
• Report patient characteristics by treatment group 
• Report summary parameters of the overall study population 
• Report median follow-up time by treatment group 
• Report reasons for censoring in the overall study population 
 
 
8. Initial Power Assessment 
 
Aetion report links: 
Optum: https://bwh-dope.aetion.com/projects/details/989/results/46159/result/0 
Marketscan: https://bwh-dope.aetion.com/projects/details/990/results/46158/result/0 
 
Date conducted: December 15, 2019 
 
In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. 
Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined 
comorbidity index. Power calculations are based on the formulas from Chow et al. (2008). 
 
In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This 
outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
10 
Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined 
comorbidity index. Power calculations are based on the formulas from Chow et al. (2008). 
 
Reviewed by PI: 
Jessica Franklin 
Date reviewed: 
12/16/19 
Reviewed by FDA: 
David Martin 
Date reviewed: 
1/2/20 
Reasons for stopping 
analysis (if required): 
 
 
 
9. Balance Assessment after PS matching 
 
Aetion report links (Prasugrel vs. clopidogrel): 
Optum: https://bwh-dope.aetion.com/projects/details/989/results/46940/result/0 
Marketscan: https://bwh-dope.aetion.com/projects/details/990/results/46941/result/0 
 
Date conducted: 01/05/2020 
 
After review of initial feasibility and power analyses, complete creation of the remaining covariates (see Table 1 below for list of 
covariates). Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS 
should include the complete list of covariates (excluding laboratory values, which are missing in some patients). 
 
• Provide plot of PS distributions stratified by treatment group. 
 
Note- Please refer to Appendix B.  
 
• Report covariate balance after matching. 
 
Note- For Table 1, please refer to Appendix B.  
 
• Report reasons for censoring by treatment group. 
  
Overall 
Referent 
Exposure 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
11 
Dummy Outcome 
0 (0.00%) 
0 (0.00%) 
0 (0.00%) 
Death 
123 (0.28%) 
70 (0.32%) 
53 (0.24%) 
Start of an additional exposure 
3,840 (8.75%) 
580 (2.64%) 
3,260 (14.86%) 
End of index exposure 
22,870 (52.14%) 
11,391 (51.94%) 
11,479 (52.34%) 
Specified date reached 
3,735 (8.51%) 
2,262 (10.31%) 
1,473 (6.72%) 
End of patient enrollment 
12,361 (28.18%) 
7,033 (32.07%) 
5,328 (24.29%) 
Switch to ticagrelor (for censoring) + nursing home 
admission 
935 (2.13%) 
596 (2.72%) 
339 (1.55%) 
 
• Report follow-up time by treatment group. 
Median Follow-Up Time (Days) [IQR] 
Patient Group 
Optum 
Marketscan 
Overall Patient Population 
276 [98-453] 
312 [122-481] 
Referent 
332 [124-532] 
344 [144-530] 
Exposure 
222 [82-405] 
281 [111-443] 
 
• Report overall risk of the primary outcome. 
  
Optum 
Marketscan 
Risk per 1,000 patients (MACE) 
58.63 
45.09 
 
10. Final Power Assessment 
 
Date conducted:  
 
• Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. 
All other parameters in the table should be the same as in Section 8. If the study is to be implemented in more than one 
database, copy and paste excel sheet to report power for each database separately and for the pooled analysis that uses data 
from all databases together. Power calculations are based on the formulas from Chow et al. (2008). 
 
o Pooled 
§ 
For prasugrel 10mg vs. clopidogrel 75mg (Primary outcome- MACE) 

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
12 
 
 
o Optum 
§ 
For prasugrel 10mg vs. clopidogrel 75mg (Primary outcome- MACE) 
• 
 
Superiority Analysis
Number of patients matched
Reference
21,932
Exposed
21,932
Risk per 1,000 patients
51.86
Desired HR from RCT
0.8
Alpha (2-sided)
0.05
Number of events expected
2274.78704
Power
0.999612288
Non-inferiority Analysis
Number of patients matched
Reference
21,932
Exposed
21,932
Risk per 1,000 patients
51.86
Assumed HR from RCT
1
Alpha (2-sided)
0.05
Non-inferiority margin
1.3
Number of events expected
2274.78704
Power
0.999991333
Superiority Analysis
Number of patients matched
Reference
6,835
Exposed
6,835
Risk per 1,000 patients
58.63
Desired HR from RCT
0.8
Alpha (2-sided)
0.05
Number of events expected
801.4721
Power
0.884670943
Non-inferiority Analysis
Number of patients matched
Reference
6,835
Exposed
6,835
Risk per 1,000 patients
58.63
Assumed HR from RCT
1
Alpha (2-sided)
0.05
Non-inferiority margin
1.3
Number of events expected
801.4721
Power
0.960270972

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
13 
 
o MarketScan 
§ 
For prasugrel 10mg vs. clopidogrel 75mg (Primary outcome- MACE) 
• 
 
 
 
• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of 
advisory board. Reviewers evaluate the results of the analyses described above in Sections 9 and 10, including numbers of 
patients, balance in patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates 
of outcomes and study power. 
Reviewed by PI: 
Jessica Franklin 
Date reviewed: 
12/16/19 
Reviewed by FDA: 
David Martin 
Date reviewed: 
01/02/2020 
Reasons for stopping 
analysis (if required): 
 
 
 
11. Study Confidence and Concerns 
 
Superiority Analysis
Number of patients matched
Reference
15,097
Exposed
15,097
Risk per 1,000 patients
45.09
Desired HR from RCT
0.8
Alpha (2-sided)
0.05
Number of events expected
1361.44746
Power
0.984488939
Non-inferiority Analysis
Number of patients matched
Reference
15,097
Exposed
15,097
Risk per 1,000 patients
45.09
Assumed HR from RCT
1
Alpha (2-sided)
0.05
Non-inferiority margin
1.3
Number of events expected
1361.44746
Power
0.998013942

Effectiveness research with Real World Data to support FDA’s regulatory decision making: Protocol Template 
 
14 
Deadline for voting on study confidence and listing concerns: 1/10/20 
 
• If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps. 
• All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the 
success of the RWD study in the Google Form. This form also provides space for reviewers to list any concerns that they feel may 
contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study 
variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the 
individual respondent. 
 
12. Register study protocol on clinicalTrials.gov 
 
Date conducted:    
 
• Register the study on clinicalTrials.gov and upload this document. 
 
13. Comparative Analyses 
 
Aetion report name: 
Date conducted:    
 
13.1 
For primary analysis:  
 
• In the PS-matched cohort from Section 9, calculate the HR for each outcome for prasugrel versus clopidogrel patients using a Cox 
proportional hazards model.  
 
13.2 
For secondary analyses: 
• In both pre-matched cohorts, perform asymmetrical trimming to remove patients with PS values below the 2.5th percentile of 
treated patients and above the 97.5th percentile of untreated patients. In the trimmed cohort, calculate the HR for prasugrel 
versus referent patients using a Cox proportional hazards model, adjusting for deciles of the PS. 
 
 

Effectiveness research with Real World Data to support FDA’s regulatory decision making 
 
 
15 
14.  Requested Results  
 
14.1 
Results from primary and secondary analyses; 
 
Analysis 
No. exposed events 
No. referent events 
Exposed rate 
Referent rate 
HR (95% CI) 
Crude 
 
 
 
 
 
Primary analysis 
 
 
 
 
 
Analysis 2 
 
 
 
 
 
... 
 
 
 
 
 
HR, Hazard Ratio; CI, Confidence Interval. 
 
15. References 
 
Aronsky, Dominik, et al. Accuracy of Administrative Data for Identifying Patients with Pneumonia. American Journal of Medical 
Quality. 2005: 20(6);319–28. doi:10.1177/1062860605280358. 
 
Chow S, Shao J, Wang H. 2008.  Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 
177 
 
Wiviott et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357:2001-15. 
 

# 
TRITON-TIMI trial definitions
Implementation in routine care
References
Color coding
Please see the following Google Drive for further details or any missing information: 
https://drive.google.com/open?id=1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV
Adequate mapping in claims
Not all ICD-10 codes are not listed in this document because of excel cell size limitations and 
excessive number of ICD-10 codes. Full ICD-10 code lists will be available in the above Google 
Drive Folder (link above). ICD-9 to ICD-10 code conversions were completed using a SAS 
macro that implements forward/ backward mapping based on the CMS ICD-9 to ICD-10 
mapping: https://www.nber.org/data/icd9-icd-10-cm-and-pcs-crosswalk-general-equivalence-
mapping.html
Intermediate mapping in claims
Prasugrel (10mg daily) vs clopidogrel (75mg daily)
Exposure: Prasugrel 10mg 
Clopidogrel 75mg 
KEY TIME POINTS: 
Index event : Onset of Acute coronary syndrome (ACS) which becomes the indication 
for study drug (prasugrel or clopidogrel) initiation 
Index hospitalization: Hospitalization for the treatment (PCI) of index event 
Drug initiation date: New prescription claim for the study drug in patients with a 
record of index hospitalization in the previous 2 weeks.
* We assume that the patient first initates study drug in hospital and continues to 
be part of the initiator group as long as a prescription is filled within 2 weeks of 
discharge of ACS event. 
Poor mapping or cannot be measured in claims 
Can't be measured in claims but not important for the analysis
Death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke 
Measured 1 day after drug initiation in diagnosis position specified below and 
inpatient care setting:
Inpatient mortality/MI/Stroke --
For MI
Any diagnosis position in inpatient care setting
ICD-9 Dx 410.X (acute myocardial infarction) excluding 410.x2 (subsequent episode 
of care)
For stroke
Primary diagnosis position in inpatient care setting 
ICD-9 discharge diagnosis:
430.xx  Subarachnoid hemorrhage (SAH)
431.xx  Intracerebral hemorrhage (ICH)
433.x1  Occlusion and stenosis of precerebral arteries with cerebral infarction
434.xx (excluding 434.x0)  Occlusion and stenosis of cerebral arteries with cerebral 
infarction
436.x  Acute, but ill-defined cerebrovascular events
Mortality- See Mortality Sheet.
For MI: 
PPV 94% in Medicare claims data [Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio 
CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute 
myocardial infarction: estimating positive predictive value on the basis of review of 
hospital records. American heart journal 2004;148:99-104.]
PPV 88.4% in commercially-insured population [Wahl PM, Rodgers K, 
Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for 
cardiovascular and gastrointestinal serious adverse events in a commercially-
insured population. Pharmacoepidemiology and Drug Safety 2010;19:596-603.]
For stroke:
PPV of 85% or higher for ischemic stroke
PPV ranging from 80% to 98% for hemorrhagic stroke
[Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated methods for 
identifying cerebrovascular accident or transient ischemic attack using 
administrative data. Pharmacoepidemiology and Drug Safety 2012;21 Suppl 1:100-
28.]
[Tirschwell DL, Longstreth WT, Jr. Validating administrative data in stroke 
research. Stroke; a journal of cerebral circulation 2002;33:2465-70.]
[Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. 
Validation of ICD-9 codes with a high positive predictive value for incident strokes 
resulting in hospitalization using Medicaid health data. Pharmacoepidemiology and 
drug safety 2008;17:20-6.]
1
Acute coronary syndrome based on the disease diagnostic criteria with planned PCI
(ACS definition; one of the following):
The hospitalization with Inpatient CPT/ICD-9 procedure code for PCI becomes the 
anchoring event for measuring 1a, 1b, 1c below. (Anchoring event = index 
hospitalization)
PCI:
CPT code: 
92920, 92921, 92924, 92925, 92928, 92929, 92933, 92934
ICD-9 procedure codes: 
00.66, 36.00, 36.06, 36.07, 36.09
Blumenthal DM, Valsdottir LR, Zhao Y, et al. A Survey of Interventional Cardiologists' 
Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. 
JAMA Cardiol. 2018;3(7):629–634. doi:10.1001/jamacardio.2018.1095
1a. 
Moderate to high risk Unstable angina:
A history of chest discomfort or ischemic symptoms of 10 min or longer at rest, 72 h or less before randomization, with 
persistent or transient ST-segment deviation 1 mm or higher in one or more
electrocardiogram (ECG) leads without elevation of creatine kinase–MB (CK-MB) or troponin T or I but with a TIMI risk score 
321 or greater
Measured 4 weeks prior to index hospitalization in inpatient, primary position 
Unstable angina: 
ICD-9 : 411.xx
ICD-10: I24.1x, I20.0x, I25.1x, I25.7x, I24.0x, I24.8x, I24.9x 
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
1b.
II. Moderate to high-risk NSTEMI:
A history of chest discomfort or ischemic symptoms of 10 min or longer at rest, 72 h or less before randomization with no 
evidence of persistent ST-segment elevation. Subjects must also have CK-MB
or troponin T or I greater than the upper limit of normal (ULN) and a TIMI risk score 3 or greater. If CK-MB or troponin is not 
available, total CK 2 times or greater ULN is acceptable
Measured 4 weeks prior to index hospitalization in inpatient, primary position 
NSTEMI: 
ICD-9: 410.7x , 410.8x, 410.9x but exclude 410.x2 (subsequent episode of care 
descriptions)
NSTEMI: 
ICD-10 :I21.4x, I21.9x, I21.Ax, I22.2x
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial 
infarction cases in the national health insurance research database in taiwan. J 
Epidemiol. 2014;24(6):500–507. doi:10.2188/jea.je20140076
1c. 
III. STEMI: 
A history of chest discomfort or ischemic symptoms of greater than 20 minutes duration at rest, within 14 days or less 
randomization with one of the following ECG features:
(a) ST-segment elevation 1 mm or higher in 2 or more contiguous
ECG leads
(b) New or presumably new left bundle branch block 
(c) ST-segment depression 1 mm or greater in 2 anterior precordial leads (V1 through V4) with clinical history and evidence 
suggestive of true posterior infarction
Measured 4 weeks prior to index hospitalization in inpatient, primary position 
STEMI:
ICD-10
I21.0x, I21.1x, I21.2x, I22.0x, I22.1x, I22.8x, I22.9x,  I23.3x, I22.0x, I22.1x, I22.8, 
I22.9
Acute MI: ICD-9 410.0x–410.6x , but exclude 410.x2 (subsequent episode of care 
descriptions)
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial 
infarction cases in the national health insurance research database in taiwan. J 
Epidemiol. 2014;24(6):500–507. doi:10.2188/jea.je20140076
2
Legal age (and >18 y) and competent mental condition to provide written informed consent
Measured at index hospitalization 
Age >18  
Trial details- HR = 0.81 (95% CI 0.73–0.90)
EXPOSURE vs. COMPARISON
PRIMARY OUTCOME
INCLUSION CRITERIA
Appendix A

3
For women of childbearing potential only, test negative for pregnancy between ACS presentation and enrollment (based on a 
urine or serum pregnancy test) and agree to use a reliable method of birth control during the study
N/A 
(We account for this criteria as an exclusion criteria)
Cardiovascular exclusion criteria
1
Cardiogenic shock at the time of randomization
Measured during index hospitalization in inpatient setting, any position
Cardiogenic shock:
ICD-9 : 785.51
ICD-10: R57.0
2
 Refractory ventricular arrhythmias
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or 
outpatient setting
Ventricular tachycardia
ICD-9: 427.1 
ICD-10: I47.2
Ventricular fibrillation 
ICD-9: 427.4x
ICD-10: I49.0x
3
New York Heart Association class IV congestive heart failure
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or 
outpatient setting. 
Heart failure diagnosis: 
Any of ICD-9 codes : 428.x, 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 
404.91, 404.03, 404.13, 404.93
AND
Oxygen use: 
E0424 E0425 E0430 E0431 E0433 E0434 E0435 E0439 E0440 E0441 E0442 
E0443 E0444 E0447 E1390 E1391 E1392 E1405 E1406 K0738 S8120 S8121
ICD-9 V46.2 (Other dependence on machines, supplemental oxygen), 
ICD-10  Z99.81 (Dependence on Supplemental oxygen)
Bleeding risk exclusion criteria
4
Fibrin-specific fibrinolytic therapy less than 24 h before randomization
N/A 
5
 Non–fibrin-specific fibrinolytic therapy less than 48 h before randomization
N/A 
6
 Active internal bleeding or history of bleeding diathesis
7
Clinical findings, in the judgment of the investigator, associated with an increased risk of bleeding
Any of the following:
a) History of hemorrhagic stroke
Measured any time prior to index hospitalization in any diagnosis position, inpatient 
or outpatient setting
Hemorrhagic stroke:
ICD-9: 430.xx, 431.xx
ICD-10: I60.xx, I61.xx, 
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
 b) Intracranial neoplasm, arteriovenous malformation, or aneurysm
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or 
outpatient setting
Intracranial neoplasm
ICD-9: 191.x, 225.0, 225.2, 225.4
ICD-10: C71.x, D32.x, D33.x, 
AV malformation (of brain)
ICD-9: 747.81
ICD-10: Q28.2x
Cerebral Aneurysm 
ICD-9: 437.3
ICD-10: I67.1
c) Ischemic stroke within 3 months prior to screening
Measured 90 days prior to index hospitalization in any position, inpatient setting. 
Ischemic stroke: 
ICD-9: 433.xx, 434.xx, 436.xx
ICD-10: I63.xx I65.xx I66.xx
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
9
 International normalized ratio known to be greater than 1.5 at the time of screening
N/A
10
Platelet count of less than 100000/mm3 at the time of screening
Measured during index hospitalization in inpatient setting, any position
Thrombocytopenia:
ICD-10: D69.6, D69.4x, D69.5x, D69.2x, D69.3x
ICD-9: 287.3x, 287.4x 
11
Anemia (hemoglobin b10 g/dL) at the time of screening
Measured during index hospitalization in inpatient setting, any position
ICD-9: 280.0 Iron deficiency anemia secondary to blood loss (chronic)
285.1 (Acute posthemorrhagic anemia), 285.9 (Anemia unspecified)
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or 
outpatient setting 
For active internal bleeding, refer to the sheet "Bleeding"
or
Bleeding diathesis:
ICD-9: 
286.x Coagulation defects
287.x Purpura and other hemorrhagic conditions
8
Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An 
automated database case definition for serious bleeding related to oral 
anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20(6):560–566. 
doi:10.1002/pds.2109
Huybrechts KF, Gopalakrishnan C, Bartels DB, Zint K, Gurusamy VK, Landon J, et al. 
Safety and effectiveness of dabigatran and other direct oral anticoagulants 
compared to warfarin in patients with atrial fibrillation. Clin Pharmacol Ther. 2019 
Dec 23.
EXCLUSION CRITERIA
Appendix A

 Prior/concomitant therapy exclusion criteria
12
 One or more doses of a thienopyridine 5 d or less before PCI
Prescription for following drugs 5 days prior to index hospitalization
Clopidogrel, prasugrel, or ticlopidine 
13
 Oral anticoagulation or other antiplatelet therapy that cannot be safely discontinued for the duration of the study
N/A
14
Daily treatment with nonsteroidal antiinflammatory drugs (NSAIDs) or cyclooxygenase-2 inhibitors (COX-2 inhibitors)
More than 150 days of supply out of 180 days prior to drug initiation 
NSAID: aspirin, ibuprofen, naproxen >> OTC cannot be captured 
COX-2 inhibitors: celecoxib 
General exclusion criteria
15
Investigative site personnel directly affiliated with the study or immediate family
N/A
16
Employed by Eli Lilly and Company; Ube Industries Limited, Daiichi Sankyo Co.; The TIMI Study Group; Quintiles
N/A
17
Treatment within the last 30 d with an investigational drug or are presently enrolled in another drug or device study
N/A
18
Previously completed or withdrawn from this study or any other study investigating prasugrel
N/A
19
Women who are known to be pregnant, have given birth within the past 90 d, or are breast-feeding
N/A
20
Concomitant medical illness that in the opinion of the investigator is associated with reduced survival
Following index score measured 180 days prior to drug initiation
Combined comorbidity index CCI >=10
Gagne, Josh J et. al. ""A combined comorbidity score predicted mortality in elderly 
patients better than existing scores."" J Clin Epidemiol. 2011 Jul;64(7):749-59. doi: 
10.1016/j.jclinepi.2010.10.004.
Sun, Jenny W et. al. ""Validation of the Combined Comorbidity Index of Charlson and 
Elixhauser to Predict 30-Day Mortality Across ICD-9 and ICD-10."" Med Care. 2018 
Sep;56(9):812. doi: 10.1097/MLR.0000000000000954.
21
Known severe hepatic dysfunction
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or 
outpatient setting 
Liver disease
ICD-9 diagnosis:
070.xx, 570.xx- 573.xx, 456.0x-456.2x, 576.8x, 782.4x, 789.5x 
ICD-9 procedure codes:
39.1x, 42.91 
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
22
Any condition associated with poor treatment compliance including alcoholism, mental illness, or drug dependence
Measured 180 days prior to drug initiation in any diagnosis position and inpatient or 
outpatient setting
Schizophrenia:  ICD-9-CM codes: 295.xx; ICD-10-CM codes: F20.xx
Psychosis:  ICD-9-CM codes: 290.8x, 290.9x, 297.xx, 298.xx, 780.1x; ICD-10-CM 
codes: F22, F23, F24, F23.3, F23.3, F28, F29, R44.0, R44.2, R44.3
Delirium:  ICD-9-CM codes: 290.11, 290.3x, 290.41, 291.0x, 292.81, 293.xx; ICD-10-
CM codes: F05, F01.51, F03.90, F10.231, F06.2, F06.0
Dementia:  ICD-9-CM codes: 290.xx, 294.1x, 294.8x, 311.19, 331.82; ICD-10-CM 
codes: F03.xx, F02.80, F02.81, G31.83, 
Drug abuse or dependence: ICD-9-CM codes: 292.xx, 304.xx, 305.2x-305.9x, 648.3x, 
760.72, 760.73, 760.75, 965.0x, 967.xx, 969.4x-969.6x, 969.72-969.79, 970.1, 
970.81 ; ICD-10-CM codes:
Alcohol abuse or dependence: ICD-9-CM codes: 291.xx, 303.xx, 305.0x, 357.5x, 
425.5x, 571.0x – 571.3x, E860.0, V11.3; ICD-10-CM codes:
Patorno, Elisabetta et al. "Cardiovascular outcomes associated with canagliflozin 
versus other non-gliflozin antidiabetic drugs: population based cohort study." BMJ 
2018;360:k119 http://dx.doi.org/10.1136/bmj.k119
Patorno, Elisabetta et al. "Empagliflozin and the Risk of Heart Failure Hospitalization 
in Routine Clinical Care: A First Analysis from the Empagliflozin Comparative 
Effectiveness and Safety (EMPRISE) Study."  Circulation. 2019 Apr 8. doi: 
10.1161/CIRCULATIONAHA.118.039177
23
Intolerance of or allergy to aspirin, tilopidine, or clopidogrel 
N/A
24
May be unable to cooperate with protocol requirements and follow-up procedures
N/A
Appendix A

Trial ID 
pNDA14
Trial Name (with web links) 
TRITON-TIMI 38
Trial Name (with pdf links)
TRITON-TIMI 38
NCT 
NCT00097591 
Trial category
Primary indication
Run-in period Description
Run-in period?
?
Therapeutic Area
Cardiology/Vascular Diseases
Study batch
Antiplatelets
RCT Category  
1a- Intended S with label change
Brand Name
Efient 
Generic Name
prasugrel
Sponsor
 Eli Lilly
Year
2009
Measurable endpoint
Primary composite endpoint of death from 
cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke. The key 
safety end point was major bleeding.
Exposure
Prasugrel
Comparator
Clopidogrel
Population
patients with moderate-to-high-risk acute 
coronary syndromes with scheduled 
percutaneous coronary intervention
Trial finding
HR = 0.81 (95% CI 0.73–0.90)
Notes
 No. of Patients 
                                                                        13,608 
Non-inferiority margin
-
Assay Sens. Outcome
Assay Sens. Endpoint (from trial)
Finding for potential Assay Sens. 
Outcome from trial- 
Power
0.90 to detect 20% reduction in the relative 
risk 
Blinding
Double-blinded
Appendix A

Statistical Method
Approval indication
 for the prevention of thrombotic 
cardiovascular complications in acute 
coronary syndromes
Appendix A

Mortality- Dependent on data source. 
1. All-cause mortality / inpatient mortality
Identified using the vital status file-
Medicare
Identified using the discharge status codes-
Optum-
• 20 = EXPIRED
• 21 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 22 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 23 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 24 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 25 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 26 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 27 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 28 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 29 = EXPIRED TO BE DEFINED AT STATE LEVEL
• 40 = EXPIRED AT HOME (HOSPICE)
• 41 = EXPIRED IN A MEDICAL FACILITY (HOSPICE)
• 42 = EXPIRED - PLACE UNKNOWN (HOSPICE)
Truven-
• 20 - Died
• 22 - Died
• 23 - Died
• 24 - Died
• 25 - Died
• 26 - Died
• 27 - Died
• 28 - Died
• 29 - Died
• 40 - Other died status or Expired at home (Hospice claims only) (depends on year)
• 41 - Other died status or Expired in medical facility (Hospice claims only) (depends on year)
Appendix A

• 42 - Other died status or Expired - place unknown (Hospice claims only) (depends on year)
• 21 - Died or Disch./Transf. to court/law enforcement (depends on year)
2. CV mortality
Information on CV mortality through data linkage with the National Death Index (NDI) will be available for Medicare 
at a later date. We will conduct secondary analyses using CV mortality at that time.
Appendix A

Major bleeding control outcome: 1 inpatient (any position)
Major bleeding exclusion criteria: 1 inpatient (any position) or 2 outpatient diagnosis (separated by 7-365 days)
562.02
 (ICD9) DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.03
 (ICD9) DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.12
 (ICD9) DIVERTICULOSIS OF COLON WITH HEMORRHAGE
562.13
 (ICD9) DIVERTICULITIS OF COLON WITH HEMORRHAGE
568.81
 (ICD9) HEMOPERITONEUM (NONTRAUMATIC)
569.3
 (ICD9) HEMORRHAGE OF RECTUM AND ANUS
569.83
 (ICD9) PERFORATION OF INTESTINE
569.85
 (ICD9) ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
569.86
 (ICD9) DIEULAFOY LESION (HEMORRHAGIC) OF INTESTINE
578
 (ICD9) HEMATEMESIS
578.9
 (ICD9) HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
423
 (ICD9) HEMOPERICARDIUM
432
 (ICD9) NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1
 (ICD9) SUBDURAL HEMORRHAGE
432.9
 (ICD9) UNSPECIFIED INTRACRANIAL HEMORRHAGE
459
 (ICD9) HEMORRHAGE UNSPECIFIED
531
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE
531
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.01
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.2
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21
 (ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.41
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT 
OBSTRUCTION
531.61
 (ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
Appendix A

532
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE
532
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.2
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21
 (ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.4
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.41
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.6
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT 
OBSTRUCTION
532.61
 (ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.2
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT 
OBSTRUCTION
533.21
 (ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.4
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT 
OBSTRUCTION
533.41
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.6
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.6
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
WITHOUT OBSTRUCTION
533.61
 (ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION 
WITH OBSTRUCTION
534
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
Appendix A

534.01
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.2
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.2
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.21
 (ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.41
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT 
OBSTRUCTION
534.61
 (ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH 
OBSTRUCTION
578.1
 (ICD9) BLOOD IN STOOL
719.1
 (ICD9) HEMARTHROSIS
719.1
 (ICD9) HEMARTHROSIS SITE UNSPECIFIED
719.11
 (ICD9) HERARTHROSIS INVOLVING SHOULDER REGION
719.12
 (ICD9) HEMARTHORSIS INVOLVING UPPER ARM
719.13
 (ICD9) HEMARTHROSIS INVOLVING FOREARM
719.14
 (ICD9) HEMARTHROSIS INVOLVING HAND
719.15
 (ICD9) HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.16
 (ICD9) HEMARTHROSIS INVOLVING LOWER LEG
719.17
 (ICD9) HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.18
 (ICD9) HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
719.19
 (ICD9) HEMARTHROSIS INVOLVING MULTIPLE SITES
430
 (ICD9) SUBARACHNOID HEMORRHAGE
431
 (ICD9) INTRACEREBRAL HEMORRHAGE
I31.2 
 (ICD10) Hemopericardium, not elsewhere classified
I60.00 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.11 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
Appendix A

I60.2 
 (ICD10) Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.30 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.31 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4 
 (ICD10) Nontraumatic subarachnoid hemorrhage from basilar artery
I60.50 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.51 
 (ICD10) Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52 
 (ICD10) Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6 
 (ICD10) Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.7 
 (ICD10) Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8 
 (ICD10) Other nontraumatic subarachnoid hemorrhage
I60.9 
 (ICD10) Nontraumatic subarachnoid hemorrhage, unspecified
I61.0 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.2 
 (ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3 
 (ICD10) Nontraumatic intracerebral hemorrhage in brain stem
I61.4 
 (ICD10) Nontraumatic intracerebral hemorrhage in cerebellum
I61.5 
 (ICD10) Nontraumatic intracerebral hemorrhage, intraventricular
I61.6 
 (ICD10) Nontraumatic intracerebral hemorrhage, multiple localized
I61.8 
 (ICD10) Other nontraumatic intracerebral hemorrhage
I61.9 
 (ICD10) Nontraumatic intracerebral hemorrhage, unspecified
I62.00 
 (ICD10) Nontraumatic subdural hemorrhage, unspecified
I62.01 
 (ICD10) Nontraumatic acute subdural hemorrhage
I62.02 
 (ICD10) Nontraumatic subacute subdural hemorrhage
I62.03 
 (ICD10) Nontraumatic chronic subdural hemorrhage
I62.1 
 (ICD10) Nontraumatic extradural hemorrhage
I62.9 
 (ICD10) Nontraumatic intracranial hemorrhage, unspecified
K25.0 
 (ICD10) Acute gastric ulcer with hemorrhage
K25.2 
 (ICD10) Acute gastric ulcer with both hemorrhage and perforation
K25.4 
 (ICD10) Chronic or unspecified gastric ulcer with hemorrhage
K25.6 
 (ICD10) Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0 
 (ICD10) Acute duodenal ulcer with hemorrhage
K26.2 
 (ICD10) Acute duodenal ulcer with both hemorrhage and perforation
Appendix A

K26.4 
 (ICD10) Chronic or unspecified duodenal ulcer with hemorrhage
K26.6 
 (ICD10) Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0 
 (ICD10) Acute peptic ulcer, site unspecified, with hemorrhage
K27.2 
 (ICD10) Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.4 
 (ICD10) Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.6 
 (ICD10) Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0 
 (ICD10) Acute gastrojejunal ulcer with hemorrhage
K28.2 
 (ICD10) Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.4 
 (ICD10) Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6 
 (ICD10) Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K55.21 
 (ICD10) Angiodysplasia of colon with hemorrhage
K56.60 
 (ICD10) Unspecified intestinal obstruction
K57.01 
 (ICD10) Diverticulitis of small intestine with perforation and abscess with bleeding
K57.11 
 (ICD10) Diverticulosis of small intestine without perforation or abscess with bleeding
K57.13 
 (ICD10) Diverticulitis of small intestine without perforation or abscess with bleeding
K57.21 
 (ICD10) Diverticulitis of large intestine with perforation and abscess with bleeding
K57.31 
 (ICD10) Diverticulosis of large intestine without perforation or abscess with bleeding
K57.33 
 (ICD10) Diverticulitis of large intestine without perforation or abscess with bleeding
K57.41 
 (ICD10) Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.51 
 (ICD10) Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53 
 (ICD10) Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.81 
 (ICD10) Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91 
 (ICD10) Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93 
 (ICD10) Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5 
 (ICD10) Hemorrhage of anus and rectum
K63.1 
 (ICD10) Perforation of intestine (nontraumatic)
K63.81 
 (ICD10) Dieulafoy lesion of intestine
K66.1 
 (ICD10) Hemoperitoneum
K92.0 
 (ICD10) Hematemesis
K92.1 
 (ICD10) Melena
K92.2 
 (ICD10) Gastrointestinal hemorrhage, unspecified
M25.00 
 (ICD10) Hemarthrosis, unspecified joint
M25.011 
 (ICD10) Hemarthrosis, right shoulder
Appendix A

M25.012 
 (ICD10) Hemarthrosis, left shoulder
M25.019 
 (ICD10) Hemarthrosis, unspecified shoulder
M25.021 
 (ICD10) Hemarthrosis, right elbow
M25.022 
 (ICD10) Hemarthrosis, left elbow
M25.029 
 (ICD10) Hemarthrosis, unspecified elbow
M25.031 
 (ICD10) Hemarthrosis, right wrist
M25.032 
 (ICD10) Hemarthrosis, left wrist
M25.039 
 (ICD10) Hemarthrosis, unspecified wrist
M25.041 
 (ICD10) Hemarthrosis, right hand
M25.042 
 (ICD10) Hemarthrosis, left hand
M25.049 
 (ICD10) Hemarthrosis, unspecified hand
M25.051 
 (ICD10) Hemarthrosis, right hip
M25.052 
 (ICD10) Hemarthrosis, left hip
M25.059 
 (ICD10) Hemarthrosis, unspecified hip
M25.061 
 (ICD10) Hemarthrosis, right knee
M25.062 
 (ICD10) Hemarthrosis, left knee
M25.069 
 (ICD10) Hemarthrosis, unspecified knee
M25.071 
 (ICD10) Hemarthrosis, right ankle
M25.072 
 (ICD10) Hemarthrosis, left ankle
M25.073 
 (ICD10) Hemarthrosis, unspecified ankle
M25.074 
 (ICD10) Hemarthrosis, right foot
M25.075 
 (ICD10) Hemarthrosis, left foot
M25.076 
 (ICD10) Hemarthrosis, unspecified foot
M25.08 
 (ICD10) Hemarthrosis, other specified site
R58 
 (ICD10) Hemorrhage, not elsewhere classified
R04 
 (ICD10) Hemorrhage from respiratory passages
R04.0 
 (ICD10) Epistaxis
R04.1 
 (ICD10) Hemorrhage from throat
R04.2 
 (ICD10) Hemoptysis
R04.8 
 (ICD10) Hemorrhage from other sites in respiratory passages
R04.81 
 (ICD10) Acute idiopathic pulmonary hemorrhage in infants
R04.89 
 (ICD10) Hemorrhage from other sites in respiratory passages
R04.9 
 (ICD10) Hemorrhage from respiratory passages, unspecified
Appendix A

R31 
 (ICD10) Hematuria
R31.0 
 (ICD10) Gross hematuria
R31.1 
 (ICD10) Benign essential microscopic hematuria
R31.2 
 (ICD10) Other microscopic hematuria
R31.21
R31.29
R31.9 
 (ICD10) Hematuria, unspecified
784.7
 (ICD9) EPISTAXIS
784.8
 (ICD9) HEMORRHAGE FROM THROAT
599.7
 (ICD9) HEMATURIA
599.7
 (ICD9) HEMATURIA UNSPECIFIED
599.71
 (ICD9) GROSS HEMATURIA
599.72
 (ICD9) MICROSCOPIC HEMATURIA
786.3
 (ICD9) HEMOPTYSIS
786.3
 (ICD9) HEMOPTYSIS UNSPECIFIED
786.31
 (ICD9) ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS
786.39
 (ICD9) OTHER HEMOPTYSIS
The occurrence of Inpatient with the following attributes:
 Procedure Code (Any Position) is any of: { “44.43”, “43255”, “0W3P8ZZ” }
44.43
 (ICD9) ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING
43255
 (HCPCS) Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method / Upper 
gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as 
appropriate; with control of bleeding, any method
0W3P8ZZ 
 (ICD10) Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic
Appendix A

AFTER PS MATCHING
Optum
MarketScan
BEFORE PS MATCHING
The c-statistics for the propensity score model, pre-matching was 0.744. The post-matching c-statistic 
was 0.538.
The c-statistics for the propensity score model, pre-matching was 0.722. The post-matching 
c-statistic was 0.528.
Appendix B

Variable
Clopidogrel 75mg
Prasugrel 10mg
St. Diff.
Clopidogrel 75mg
Prasugrel 10mg
St. Diff.
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Number of patients
                               32,556                                   6,872 
                                 50,795                                  15,187 
                             83,351                              22,059 
Age
...mean (sd)
65.63 (12.12)
58.97 (10.27)
0.59
60.92 (11.98)
56.08 (8.96)
0.46
62.76 (12.03)
56.98 (9.39)
0.54
...median [IQR]
67.00 [57.00, 75.00] 59.00 [52.00, 67.00]
0.71
60.00 [53.00, 68.00]
57.00 [50.00, 62.00]
0.28
62.73 (12.03)
57.62 (9.39)
0.47
Age categories
...18 - 54; n (%)
6,488 (19.9%)
2,342 (34.1%)
-0.32
15,420 (30.4%)
6,296 (41.5%)
-0.23
21,908 (26.3%)
8,638 (39.2%)
-0.28
...55 - 64; n (%)
7,900 (24.3%)
2,300 (33.5%)
-0.20
19,596 (38.6%)
6,745 (44.4%)
-0.12
27,496 (33.0%)
9,045 (41.0%)
-0.17
...65 - 74; n (%)
9,646 (29.6%)
1,861 (27.1%)
0.06
7,876 (15.5%)
1,834 (12.1%)
0.10
17,522 (21.0%)
3,695 (16.8%)
0.11
...>= 75; n (%)
8,522 (26.2%)
369 (5.4%)
0.59
7,903 (15.6%)
312 (2.1%)
0.49
16,425 (19.7%)
0,681 (3.1%)
0.54
Gender- United
...Males; n (%)
21,743 (66.8%)
5,279 (76.8%)
-0.22
36,413 (71.7%)
12,111 (79.7%)
-0.19
58,156 (69.8%)
17,390 (78.8%)
-0.21
...Females; n (%)
10,813 (33.2%)
1,593 (23.2%)
0.22
14,382 (28.3%)
3,076 (20.3%)
0.19
25,195 (30.2%)
4,669 (21.2%)
0.21
Region
...Northeast; n (%)
3,792 (11.6%)
520 (7.6%)
0.14
9,397 (18.5%)
2,412 (15.9%)
0.07
13,189 (15.8%)
2,932 (13.3%)
0.07
...South; n (%)
13,415 (41.2%)
3,530 (51.4%)
-0.21
15,086 (29.7%)
3,797 (25.0%)
0.11
28,501 (34.2%)
7,327 (33.2%)
0.02
...Midwest; n (%)
9,686 (29.8%)
1,655 (24.1%)
0.13
17,860 (35.2%)
6,576 (43.3%)
-0.17
27,546 (33.0%)
8,231 (37.3%)
-0.09
...West; n (%)
5,663 (17.4%)
1,167 (17.0%)
0.01
7,896 (15.5%)
2,181 (14.4%)
0.03
13,559 (16.3%)
3,348 (15.2%)
0.03
...Unknown+missing; n (%)
N/A
N/A
#VALUE!
556 (1.1%)
221 (1.5%)
-0.04
556 (0.7%)
221 (1.0%)
-0.03
CV Covariates
Ischemic heart disease; n (%)
32,556 (100.0%)
6,872 (100.0%)
#DIV/0!
50,795 (100.0%)
15,187 (100.0%)
#DIV/0!
83,351 (100.0%)
22,059 (100.0%)
#DIV/0!
Acute MI; n (%)
30,440 (93.5%)
6,584 (95.8%)
-0.10
49,272 (97.0%)
14,846 (97.8%)
-0.05
79712 (95.6%)
21430 (97.1%)
-0.08
ACS/unstable angina; n (%)
13,130 (40.3%)
2,491 (36.2%)
0.08
16,600 (32.7%)
4,707 (31.0%)
0.04
29730 (35.7%)
7198 (32.6%)
0.07
Old MI; n (%)
4,370 (13.4%)
739 (10.8%)
0.08
3,850 (7.6%)
1,014 (6.7%)
0.03
8220 (9.9%)
1753 (7.9%)
0.07
Stable angina; n (%)
6,311 (19.4%)
1,068 (15.5%)
0.10
5,813 (11.4%)
1,663 (11.0%)
0.01
12,124 (14.5%)
2,731 (12.4%)
0.06
Coronary atherosclerosis and other forms 
of chronic ischemic heart disease; n (%)
31,630 (97.2%)
6,662 (96.9%)
0.02
46,490 (91.5%)
13,861 (91.3%)
0.01
78,120 (93.7%)
20,523 (93.0%)
0.03
Other atherosclerosis with ICD10  ; n (%)
560 (1.7%)
97 (1.4%)
0.02
782 (1.5%)
157 (1.0%)
0.05
1342 (1.6%)
254 (1.2%)
0.03
Previous cardiac procedure (CABG or PTCA 
or Stent) ; n (%)
31,882 (97.9%)
6,786 (98.7%)
-0.06
49,694 (97.8%)
14,936 (98.3%)
-0.04
81576 (97.9%)
21722 (98.5%)
-0.05
History of CABG or PTCA; n (%)
9,533 (29.3%)
1,631 (23.7%)
0.13
7,438 (14.6%)
1,995 (13.1%)
0.04
16,971 (20.4%)
3,626 (16.4%)
0.10
Any stroke; n (%)
2,400 (7.4%)
287 (4.2%)
0.14
2,470 (4.9%)
390 (2.6%)
0.12
4,870 (5.8%)
0,677 (3.1%)
0.13
Ischemic stroke (w and w/o mention of 
cerebral infarction); n (%)
2,399 (7.4%)
287 (4.2%)
0.14
2,470 (4.9%)
390 (2.6%)
0.12
4,869 (5.8%)
0,677 (3.1%)
0.13
Hemorrhagic stroke; n (%)
1 (0.0%)
0 (0.0%)
#DIV/0!
1 (0.0%)
0 (0.0%)
#DIV/0!
2 (0.0%)
0 (0.0%)
#DIV/0!
TIA; n (%)
480 (1.5%)
46 (0.7%)
0.08
523 (1.0%)
63 (0.4%)
0.07
1003 (1.2%)
109 (0.5%)
0.08
Other cerebrovascular disease; n (%)
450 (1.4%)
43 (0.6%)
0.08
388 (0.8%)
46 (0.3%)
0.07
838 (1.0%)
89 (0.4%)
0.07
Late effects of cerebrovascular disease; n 
(%)
396 (1.2%)
28 (0.4%)
0.09
291 (0.6%)
21 (0.1%)
0.08
687 (0.8%)
49 (0.2%)
0.09
Cerebrovascular procedure; n (%)
16 (0.0%)
1 (0.0%)
#DIV/0!
34 (0.1%)
1 (0.0%)
0.04
50 (0.1%)
2 (0.0%)
0.04
Heart failure (CHF); n (%)
6,838 (21.0%)
941 (13.7%)
0.19
7,137 (14.1%)
1,632 (10.7%)
0.10
13,975 (16.8%)
2,573 (11.7%)
0.15
Peripheral Vascular Disease (PVD) or PVD 
Surgery ; n (%)
2,702 (8.3%)
361 (5.3%)
0.12
2,268 (4.5%)
413 (2.7%)
0.10
4,970 (6.0%)
0,774 (3.5%)
0.12
Unmatched
Optum
Truven
POOLED
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Atrial fibrillation; n (%)
4,283 (13.2%)
413 (6.0%)
0.25
4,104 (8.1%)
574 (3.8%)
0.18
8,387 (10.1%)
0,987 (4.5%)
0.22
Other cardiac dysrhythmia; n (%)
9,981 (30.7%)
1,632 (23.7%)
0.16
10,768 (21.2%)
2,653 (17.5%)
0.09
20,749 (24.9%)
4,285 (19.4%)
0.13
Cardiac conduction disorders; n (%)
4,606 (14.1%)
639 (9.3%)
0.15
4,344 (8.6%)
958 (6.3%)
0.09
8950 (10.7%)
1597 (7.2%)
0.12
Other CVD; n (%)
11,182 (34.3%)
1,890 (27.5%)
0.15
12,049 (23.7%)
3,160 (20.8%)
0.07
23,231 (27.9%)
5,050 (22.9%)
0.12
Diabetes-related complications
Diabetic retinopathy; n (%)
742 (2.3%)
140 (2.0%)
0.02
641 (1.3%)
152 (1.0%)
0.03
1,383 (1.7%)
0,292 (1.3%)
0.03
Diabetes with other ophthalmic 
manifestations; n (%)
61 (0.2%)
6 (0.1%)
0.03
426 (0.8%)
109 (0.7%)
0.01
0,487 (0.6%)
0,115 (0.5%)
0.01
Retinal detachment, vitreous hemorrhage, 
vitrectomy; n (%)
15 (0.0%)
1 (0.0%)
#DIV/0!
15 (0.0%)
4 (0.0%)
#DIV/0!
30 (0.0%)
5 (0.0%)
#DIV/0!
Retinal laser coagulation therapy; n (%)
63 (0.2%)
11 (0.2%)
0.00
103 (0.2%)
28 (0.2%)
0.00
166 (0.2%)
39 (0.2%)
0.00
Occurrence of Diabetic Neuropathy  ; n (%)
2,028 (6.2%)
331 (4.8%)
0.06
1,485 (2.9%)
353 (2.3%)
0.04
3,513 (4.2%)
0,684 (3.1%)
0.06
Occurrence of diabetic nephropathy  with 
ICD10 ; n (%)
1,915 (5.9%)
238 (3.5%)
0.11
994 (2.0%)
203 (1.3%)
0.05
2,909 (3.5%)
0,441 (2.0%)
0.09
Hypoglycemia ; n (%)
396 (1.2%)
71 (1.0%)
0.02
608 (1.2%)
138 (0.9%)
0.03
1,004 (1.2%)
0,209 (0.9%)
0.03
Hyperglycemia; n (%)
2,444 (7.5%)
521 (7.6%)
0.00
2,152 (4.2%)
697 (4.6%)
-0.02
4,596 (5.5%)
1,218 (5.5%)
0.00
Disorders of fluid electrolyte and acid-base 
balance; n (%)
4,694 (14.4%)
808 (11.8%)
0.08
4,163 (8.2%)
1,078 (7.1%)
0.04
8,857 (10.6%)
1,886 (8.5%)
0.07
Diabetic ketoacidosis; n (%)
127 (0.4%)
22 (0.3%)
0.02
182 (0.4%)
53 (0.3%)
0.02
309 (0.4%)
75 (0.3%)
0.02
Hyperosmolar hyperglycemic nonketotic 
syndrome (HONK); n (%)
81 (0.2%)
18 (0.3%)
-0.02
54 (0.1%)
14 (0.1%)
0.00
135 (0.2%)
32 (0.1%)
0.03
Diabetes with peripheral circulatory 
disorders with ICD-10  ; n (%)
946 (2.9%)
101 (1.5%)
0.10
537 (1.1%)
126 (0.8%)
0.03
1,483 (1.8%)
0,227 (1.0%)
0.07
Diabetic Foot; n (%)
374 (1.1%)
54 (0.8%)
0.03
378 (0.7%)
92 (0.6%)
0.01
752 (0.9%)
146 (0.7%)
0.02
Gangrene ; n (%)
39 (0.1%)
4 (0.1%)
0.00
30 (0.1%)
9 (0.1%)
0.00
69 (0.1%)
13 (0.1%)
0.00
Lower extremity amputation; n (%)
145 (0.4%)
22 (0.3%)
0.02
67 (0.1%)
23 (0.2%)
-0.03
212 (0.3%)
45 (0.2%)
0.02
Osteomyelitis; n (%)
99 (0.3%)
16 (0.2%)
0.02
110 (0.2%)
21 (0.1%)
0.03
209 (0.3%)
37 (0.2%)
0.02
Skin infections ; n (%)
1,316 (4.0%)
240 (3.5%)
0.03
1,628 (3.2%)
437 (2.9%)
0.02
2,944 (3.5%)
0,677 (3.1%)
0.02
Erectile dysfunction; n (%)
856 (2.6%)
240 (3.5%)
-0.05
1,014 (2.0%)
329 (2.2%)
-0.01
1,870 (2.2%)
0,569 (2.6%)
-0.03
Diabetes with unspecified complication; n 
(%)
759 (2.3%)
148 (2.2%)
0.01
696 (1.4%)
246 (1.6%)
-0.02
1,455 (1.7%)
0,394 (1.8%)
-0.01
Diabetes mellitus without mention of 
complications; n (%)
10,901 (33.5%)
2,146 (31.2%)
0.05
13,531 (26.6%)
3,957 (26.1%)
0.01
24,432 (29.3%)
6,103 (27.7%)
0.04
Hypertension: 1 inpatient or 2 outpatient 
claims within 365 days; n (%)
26,001 (79.9%)
5,031 (73.2%)
0.16
33,778 (66.5%)
9,642 (63.5%)
0.06
59,779 (71.7%)
14,673 (66.5%)
0.11
Hyperlipidemia ; n (%)
26,353 (80.9%)
5,585 (81.3%)
-0.01
32,023 (63.0%)
10,002 (65.9%)
-0.06
58,376 (70.0%)
15,587 (70.7%)
-0.02
Edema; n (%)
1,711 (5.3%)
184 (2.7%)
0.13
1,267 (2.5%)
262 (1.7%)
0.06
2,978 (3.6%)
0,446 (2.0%)
0.10
Renal Dysfunction (non-diabetic) ; n (%)
6,929 (21.3%)
936 (13.6%)
0.20
5,898 (11.6%)
1,168 (7.7%)
0.13
12,827 (15.4%)
2,104 (9.5%)
0.18
Occurrence of acute renal disease ; n (%)
2,912 (8.9%)
403 (5.9%)
0.11
2,293 (4.5%)
488 (3.2%)
0.07
5205 (6.2%)
891 (4.0%)
0.10
Occurrence of chronic renal insufficiency; 
n (%)
4,727 (14.5%)
549 (8.0%)
0.21
3,259 (6.4%)
558 (3.7%)
0.12
7,986 (9.6%)
1,107 (5.0%)
0.18
Chronic kidney disease ; n (%)
4,603 (14.1%)
526 (7.7%)
0.21
3,172 (6.2%)
537 (3.5%)
0.13
7,775 (9.3%)
1,063 (4.8%)
0.18
CKD Stage 3-4; n (%)
2,896 (8.9%)
296 (4.3%)
0.19
1,875 (3.7%)
284 (1.9%)
0.11
4,771 (5.7%)
0,580 (2.6%)
0.16
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of hypertensive nephropathy; 
n (%)
3,749 (11.5%)
412 (6.0%)
0.20
2,431 (4.8%)
415 (2.7%)
0.11
6180 (7.4%)
827 (3.7%)
0.16
Occurrence of miscellaneous renal 
insufficiency ; n (%)
2,374 (7.3%)
359 (5.2%)
0.09
1,923 (3.8%)
418 (2.8%)
0.06
4,297 (5.2%)
0,777 (3.5%)
0.08
Glaucoma or cataracts ; n (%)
4,247 (13.0%)
576 (8.4%)
0.15
4,713 (9.3%)
902 (5.9%)
0.13
8,960 (10.7%)
1,478 (6.7%)
0.14
Cellulitis or abscess of toe; n (%)
276 (0.8%)
33 (0.5%)
0.04
173 (0.3%)
48 (0.3%)
0.00
449 (0.5%)
81 (0.4%)
0.01
Foot ulcer; n (%)
376 (1.2%)
52 (0.8%)
0.04
379 (0.7%)
92 (0.6%)
0.01
755 (0.9%)
144 (0.7%)
0.02
Bladder stones; n (%)
57 (0.2%)
7 (0.1%)
0.03
48 (0.1%)
8 (0.1%)
0.00
105 (0.1%)
15 (0.1%)
0.00
Kidney stones; n (%)
729 (2.2%)
143 (2.1%)
0.01
857 (1.7%)
258 (1.7%)
0.00
1,586 (1.9%)
0,401 (1.8%)
0.01
Urinary tract infections (UTIs); n (%)
2,281 (7.0%)
303 (4.4%)
0.11
2,080 (4.1%)
441 (2.9%)
0.07
4,361 (5.2%)
0,744 (3.4%)
0.09
Dipstick urinalysis; n (%)
7,433 (22.8%)
1,375 (20.0%)
0.07
10,098 (19.9%)
3,062 (20.2%)
-0.01
17,531 (21.0%)
4,437 (20.1%)
0.02
Non-dipstick urinalysis; n (%)
3,761 (11.6%)
666 (9.7%)
0.06
3,775 (7.4%)
1,224 (8.1%)
-0.03
7,536 (9.0%)
1,890 (8.6%)
0.01
Urine function test; n (%)
682 (2.1%)
108 (1.6%)
0.04
934 (1.8%)
189 (1.2%)
0.05
1,616 (1.9%)
0,297 (1.3%)
0.05
Cytology; n (%)
332 (1.0%)
45 (0.7%)
0.03
497 (1.0%)
87 (0.6%)
0.04
829 (1.0%)
132 (0.6%)
0.04
Cystos; n (%)
468 (1.4%)
61 (0.9%)
0.05
640 (1.3%)
113 (0.7%)
0.06
1108 (1.3%)
174 (0.8%)
0.05
Other Covariates
Liver disease; n (%)
11 (0.0%)
2 (0.0%)
#DIV/0!
9 (0.0%)
6 (0.0%)
#DIV/0!
0,020 (0.0%)
0,008 (0.0%)
#DIV/0!
Osteoarthritis; n (%)
5,215 (16.0%)
796 (11.6%)
0.13
4,978 (9.8%)
1,170 (7.7%)
0.07
10,193 (12.2%)
1,966 (8.9%)
0.11
Other arthritis, arthropathies and 
musculoskeletal pain; n (%)
11,251 (34.6%)
2,072 (30.2%)
0.09
13,878 (27.3%)
3,718 (24.5%)
0.06
25,129 (30.1%)
5,790 (26.2%)
0.09
Dorsopathies; n (%)
7,629 (23.4%)
1,462 (21.3%)
0.05
9,142 (18.0%)
2,497 (16.4%)
0.04
16,771 (20.1%)
3,959 (17.9%)
0.06
Fractures; n (%)
758 (2.3%)
116 (1.7%)
0.04
879 (1.7%)
209 (1.4%)
0.02
1,637 (2.0%)
0,325 (1.5%)
0.04
Falls ; n (%)
742 (2.3%)
85 (1.2%)
0.08
316 (0.6%)
54 (0.4%)
0.03
1058 (1.3%)
139 (0.6%)
0.07
Osteoporosis; n (%)
1,494 (4.6%)
137 (2.0%)
0.15
1,313 (2.6%)
149 (1.0%)
0.12
2,807 (3.4%)
0,286 (1.3%)
0.14
Hyperthyroidism; n (%)
181 (0.6%)
34 (0.5%)
0.01
189 (0.4%)
37 (0.2%)
0.04
370 (0.4%)
71 (0.3%)
0.02
Hypothyroidism ; n (%)
4,397 (13.5%)
682 (9.9%)
0.11
4,244 (8.4%)
992 (6.5%)
0.07
8,641 (10.4%)
1,674 (7.6%)
0.10
Other disorders of thyroid gland ; n (%)
750 (2.3%)
131 (1.9%)
0.03
867 (1.7%)
225 (1.5%)
0.02
1,617 (1.9%)
0,356 (1.6%)
0.02
Depression; n (%)
3,047 (9.4%)
634 (9.2%)
0.01
3,332 (6.6%)
907 (6.0%)
0.02
6,379 (7.7%)
1,541 (7.0%)
0.03
Anxiety; n (%)
3,443 (10.6%)
720 (10.5%)
0.00
3,184 (6.3%)
1,000 (6.6%)
-0.01
6,627 (8.0%)
1,720 (7.8%)
0.01
Sleep_Disorder; n (%)
2,282 (7.0%)
594 (8.6%)
-0.06
3,772 (7.4%)
1,215 (8.0%)
-0.02
6,054 (7.3%)
1,809 (8.2%)
-0.03
Dementia; n (%)
487 (1.5%)
22 (0.3%)
0.13
413 (0.8%)
38 (0.3%)
0.07
900 (1.1%)
60 (0.3%)
0.10
Delirium; n (%)
197 (0.6%)
20 (0.3%)
0.04
147 (0.3%)
23 (0.2%)
0.02
344 (0.4%)
43 (0.2%)
0.04
Psychosis; n (%)
19 (0.1%)
2 (0.0%)
0.04
16 (0.0%)
2 (0.0%)
#DIV/0!
35 (0.0%)
4 (0.0%)
#DIV/0!
Obesity; n (%)
6,887 (21.2%)
1,604 (23.3%)
-0.05
7,002 (13.8%)
2,329 (15.3%)
-0.04
13,889 (16.7%)
3,933 (17.8%)
-0.03
Overweight; n (%)
1,386 (4.3%)
255 (3.7%)
0.03
816 (1.6%)
259 (1.7%)
-0.01
2,202 (2.6%)
0,514 (2.3%)
0.02
Smoking; n (%)
14,928 (45.9%)
3,204 (46.6%)
-0.01
15,361 (30.2%)
4,812 (31.7%)
-0.03
30,289 (36.3%)
8,016 (36.3%)
0.00
Alcohol abuse or dependence; n (%)
4 (0.0%)
0 (0.0%)
#DIV/0!
504 (1.0%)
170 (1.1%)
-0.01
508 (0.6%)
170 (0.8%)
-0.02
Drug abuse or dependence; n (%)
8 (0.0%)
2 (0.0%)
#DIV/0!
2 (0.0%)
0 (0.0%)
#DIV/0!
10 (0.0%)
2 (0.0%)
#DIV/0!
COPD; n (%)
5,055 (15.5%)
674 (9.8%)
0.17
4,803 (9.5%)
964 (6.3%)
0.12
9,858 (11.8%)
1,638 (7.4%)
0.15
Asthma; n (%)
2,227 (6.8%)
403 (5.9%)
0.04
2,515 (5.0%)
621 (4.1%)
0.04
4,742 (5.7%)
1,024 (4.6%)
0.05
Obstructive sleep apnea; n (%)
2,734 (8.4%)
634 (9.2%)
-0.03
3,200 (6.3%)
1,045 (6.9%)
-0.02
5,934 (7.1%)
1,679 (7.6%)
-0.02
Pneumonia; n (%)
1,627 (5.0%)
238 (3.5%)
0.07
1,716 (3.4%)
358 (2.4%)
0.06
3,343 (4.0%)
0,596 (2.7%)
0.07
Imaging; n (%)
698 (2.1%)
132 (1.9%)
0.01
4,713 (9.3%)
133 (0.9%)
0.39
1138 (1.4%)
265 (1.2%)
0.02
Other Medications
Use of ACE inhibitors; n (%)
17,584 (54.0%)
3,742 (54.5%)
-0.01
29,471 (58.0%)
9,091 (59.9%)
-0.04
47,055 (56.5%)
12,833 (58.2%)
-0.03
Use of ARBs; n (%)
5,799 (17.8%)
1,182 (17.2%)
0.02
8,108 (16.0%)
2,346 (15.4%)
0.02
13,907 (16.7%)
3,528 (16.0%)
0.02
Use of Loop Diuretics - United; n (%)
3,974 (12.2%)
449 (6.5%)
0.20
4,290 (8.4%)
720 (4.7%)
0.15
8,264 (9.9%)
1,169 (5.3%)
0.17
Use of other diuretics- United; n (%)
1,162 (3.6%)
249 (3.6%)
0.00
1,686 (3.3%)
520 (3.4%)
-0.01
2,848 (3.4%)
0,769 (3.5%)
-0.01
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Use of nitrates-United; n (%)
14,693 (45.1%)
2,981 (43.4%)
0.03
24,231 (47.7%)
6,928 (45.6%)
0.04
38,924 (46.7%)
9,909 (44.9%)
0.04
Use of other hypertension drugs; n (%)
2,065 (6.3%)
271 (3.9%)
0.11
2,486 (4.9%)
513 (3.4%)
0.08
4,551 (5.5%)
0,784 (3.6%)
0.09
Use of digoxin- United; n (%)
517 (1.6%)
49 (0.7%)
0.08
749 (1.5%)
94 (0.6%)
0.09
1266 (1.5%)
143 (0.6%)
0.09
Use of Anti-arrhythmics; n (%)
897 (2.8%)
88 (1.3%)
0.11
1,065 (2.1%)
171 (1.1%)
0.08
1962 (2.4%)
259 (1.2%)
0.09
Use of COPD/asthma meds- United; n (%)
4,160 (12.8%)
750 (10.9%)
0.06
6,088 (12.0%)
1,656 (10.9%)
0.03
10,248 (12.3%)
2,406 (10.9%)
0.04
Use of statins; n (%)
29,217 (89.7%)
6,272 (91.3%)
-0.05
45,797 (90.2%)
13,815 (91.0%)
-0.03
75,014 (90.0%)
20,087 (91.1%)
-0.04
Use of other lipid-lowering drugs; n (%)
2,494 (7.7%)
609 (8.9%)
-0.04
4,655 (9.2%)
1,435 (9.4%)
-0.01
7,149 (8.6%)
2,044 (9.3%)
-0.02
Use of oral anticoagulants (Dabigatran, 
Rivaroxaban, Apixaban, Warfarin); n (%)
2,662 (8.2%)
171 (2.5%)
0.26
3,286 (6.5%)
393 (2.6%)
0.19
5,948 (7.1%)
0,564 (2.6%)
0.21
Use of heparin and other low-molecular 
weight heparins; n (%)
330 (1.0%)
29 (0.4%)
0.07
2 (0.0%)
3 (0.0%)
#DIV/0!
332 (0.4%)
32 (0.1%)
0.06
Use of NSAIDs; n (%)
4,155 (12.8%)
898 (13.1%)
-0.01
6,384 (12.6%)
1,965 (12.9%)
-0.01
10,539 (12.6%)
2,863 (13.0%)
-0.01
Use of oral corticosteroids; n (%)
5,465 (16.8%)
953 (13.9%)
0.08
7,355 (14.5%)
2,031 (13.4%)
0.03
12,820 (15.4%)
2,984 (13.5%)
0.05
Use of bisphosphonate (United); n (%)
604 (1.9%)
58 (0.8%)
0.10
773 (1.5%)
82 (0.5%)
0.10
1377 (1.7%)
140 (0.6%)
0.10
Use of opioids- United; n (%)
7,601 (23.3%)
1,567 (22.8%)
0.01
11,530 (22.7%)
3,264 (21.5%)
0.03
19,131 (23.0%)
4,831 (21.9%)
0.03
Use of antidepressants; n (%)
5,200 (16.0%)
1,058 (15.4%)
0.02
7,509 (14.8%)
2,093 (13.8%)
0.03
12,709 (15.2%)
3,151 (14.3%)
0.03
Use of antipsychotics; n (%)
292 (0.9%)
44 (0.6%)
0.03
396 (0.8%)
108 (0.7%)
0.01
0,688 (0.8%)
0,152 (0.7%)
0.01
Use of anticonvulsants; n (%)
3,010 (9.2%)
498 (7.2%)
0.07
3,327 (6.5%)
789 (5.2%)
0.06
6,337 (7.6%)
1,287 (5.8%)
0.07
Use of lithium- United; n (%)
31 (0.1%)
7 (0.1%)
0.00
60 (0.1%)
17 (0.1%)
0.00
91 (0.1%)
24 (0.1%)
0.00
Use of Benzos- United; n (%)
2,919 (9.0%)
668 (9.7%)
-0.02
5,195 (10.2%)
1,421 (9.4%)
0.03
8,114 (9.7%)
2,089 (9.5%)
0.01
Use of anxiolytics/hypnotics- United; n (%)
1,506 (4.6%)
352 (5.1%)
-0.02
2,651 (5.2%)
818 (5.4%)
-0.01
4,157 (5.0%)
1,170 (5.3%)
-0.01
Use of dementia meds- United; n (%)
178 (0.5%)
14 (0.2%)
0.05
252 (0.5%)
13 (0.1%)
0.07
430 (0.5%)
27 (0.1%)
0.07
Use of antiparkinsonian meds- United; n 
(%)
547 (1.7%)
63 (0.9%)
0.07
652 (1.3%)
118 (0.8%)
0.05
1,199 (1.4%)
0,181 (0.8%)
0.06
Entresto (sacubitril/valsartan); n (%)
22 (0.1%)
2 (0.0%)
0.04
3 (0.0%)
2 (0.0%)
#DIV/0!
25 (0.0%)
4 (0.0%)
#DIV/0!
Labs
0
0
Lab values- HbA1c (%) ; n (%)
3,678 (11.3%)
668 (9.7%)
0.05
559 (1.1%)
130 (0.9%)
0.02
4,237 (5.1%)
0,798 (3.6%)
0.07
Lab values- HbA1c (%) (within 3 months) ; n 
(%)
2,396 (7.4%)
415 (6.0%)
0.06
395 (0.8%)
79 (0.5%)
0.04
2,791 (3.3%)
0,494 (2.2%)
0.07
Lab values- HbA1c (%) (within 6 months) ; n 
(%)
3,678 (11.3%)
668 (9.7%)
0.05
559 (1.1%)
130 (0.9%)
0.02
4,237 (5.1%)
0,798 (3.6%)
0.07
Lab values- BNP; n (%)
257 (0.8%)
31 (0.5%)
0.04
41 (0.1%)
6 (0.0%)
0.04
298 (0.4%)
37 (0.2%)
0.04
Lab values- BNP (within 3 months); n (%)
200 (0.6%)
26 (0.4%)
0.03
37 (0.1%)
5 (0.0%)
0.04
237 (0.3%)
31 (0.1%)
0.04
Lab values- BNP (within 6 months); n (%)
257 (0.8%)
31 (0.5%)
0.04
41 (0.1%)
6 (0.0%)
0.04
298 (0.4%)
37 (0.2%)
0.04
Lab values- BUN (mg/dl); n (%)
6,259 (19.2%)
1,248 (18.2%)
0.03
444 (0.9%)
144 (0.9%)
0.00
6,703 (8.0%)
1,392 (6.3%)
0.07
Lab values- BUN (mg/dl) (within 3 months); 
n (%)
4,032 (12.4%)
755 (11.0%)
0.04
306 (0.6%)
95 (0.6%)
0.00
4,338 (5.2%)
0,850 (3.9%)
0.06
Lab values- BUN (mg/dl) (within 6 months); 
n (%)
6,259 (19.2%)
1,248 (18.2%)
0.03
444 (0.9%)
144 (0.9%)
0.00
6,703 (8.0%)
1,392 (6.3%)
0.07
Lab values- Creatinine (mg/dl) ; n (%)
6,410 (19.7%)
1,279 (18.6%)
0.03
467 (0.9%)
153 (1.0%)
-0.01
6,877 (8.3%)
1,432 (6.5%)
0.07
Lab values- Creatinine (mg/dl) (within 3 
months) ; n (%)
4,139 (12.7%)
775 (11.3%)
0.04
317 (0.6%)
100 (0.7%)
-0.01
4,456 (5.3%)
0,875 (4.0%)
0.06
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Lab values- Creatinine (mg/dl) (within 6 
months) ; n (%)
6,410 (19.7%)
1,279 (18.6%)
0.03
467 (0.9%)
153 (1.0%)
-0.01
6,877 (8.3%)
1,432 (6.5%)
0.07
Lab values- HDL level (mg/dl); n (%)
4,980 (15.3%)
1,064 (15.5%)
-0.01
506 (1.0%)
130 (0.9%)
0.01
5,486 (6.6%)
1,194 (5.4%)
0.05
Lab values- HDL level (mg/dl) (within 3 
months); n (%)
3,015 (9.3%)
623 (9.1%)
0.01
333 (0.7%)
85 (0.6%)
0.01
3,348 (4.0%)
0,708 (3.2%)
0.04
Lab values- HDL level (mg/dl) (within 6 
months); n (%)
4,980 (15.3%)
1,064 (15.5%)
-0.01
506 (1.0%)
130 (0.9%)
0.01
5,486 (6.6%)
1,194 (5.4%)
0.05
Lab values- LDL level (mg/dl) ; n (%)
5,080 (15.6%)
1,074 (15.6%)
0.00
571 (1.1%)
135 (0.9%)
0.02
5,651 (6.8%)
1,209 (5.5%)
0.05
Lab values- LDL level (mg/dl) (within 3 
months) ; n (%)
3,064 (9.4%)
626 (9.1%)
0.01
400 (0.8%)
87 (0.6%)
0.02
3,464 (4.2%)
0,713 (3.2%)
0.05
Lab values- LDL level (mg/dl) (within 6 
months) ; n (%)
5,080 (15.6%)
1,074 (15.6%)
0.00
571 (1.1%)
135 (0.9%)
0.02
5,651 (6.8%)
1,209 (5.5%)
0.05
Lab values- NT-proBNP; n (%)
36 (0.1%)
7 (0.1%)
0.00
1 (0.0%)
0 (0.0%)
#DIV/0!
37 (0.0%)
7 (0.0%)
#DIV/0!
Lab values- NT-proBNP (within 3 months); 
n (%)
28 (0.1%)
6 (0.1%)
0.00
1 (0.0%)
0 (0.0%)
#DIV/0!
29 (0.0%)
6 (0.0%)
#DIV/0!
Lab values- NT-proBNP (within 6 months); 
n (%)
36 (0.1%)
7 (0.1%)
0.00
1 (0.0%)
0 (0.0%)
#DIV/0!
37 (0.0%)
7 (0.0%)
#DIV/0!
Lab values- Total cholesterol (mg/dl) ; n (%)
5,029 (15.4%)
1,068 (15.5%)
0.00
510 (1.0%)
131 (0.9%)
0.01
5,539 (6.6%)
1,199 (5.4%)
0.05
Lab values- Total cholesterol (mg/dl) 
(within 3 months) ; n (%)
3,031 (9.3%)
621 (9.0%)
0.01
339 (0.7%)
85 (0.6%)
0.01
3,370 (4.0%)
0,706 (3.2%)
0.04
Lab values- Total cholesterol (mg/dl) 
(within 6 months) ; n (%)
5,029 (15.4%)
1,068 (15.5%)
0.00
510 (1.0%)
131 (0.9%)
0.01
5,539 (6.6%)
1,199 (5.4%)
0.05
Lab values- Triglyceride level (mg/dl); n (%)
4,942 (15.2%)
1,070 (15.6%)
-0.01
497 (1.0%)
129 (0.8%)
0.02
5,439 (6.5%)
1,199 (5.4%)
0.05
Lab values- Triglyceride level (mg/dl) 
(within 3 months); n (%)
2,969 (9.1%)
623 (9.1%)
0.00
325 (0.6%)
84 (0.6%)
0.00
3,294 (4.0%)
0,707 (3.2%)
0.04
Lab values- Triglyceride level (mg/dl) 
(within 6 months); n (%)
4,942 (15.2%)
1,070 (15.6%)
-0.01
497 (1.0%)
129 (0.8%)
0.02
5,439 (6.5%)
1,199 (5.4%)
0.05
Lab result number- HbA1c (%) mean (only 2 
to 20 included) 
                                  3,659                                       664 
                                        434                                         118 
0
0
...mean (sd)
7.12 (1.74)
7.18 (1.76)
-0.03
8.08 (1.93)
8.20 (1.99)
-0.06
7.71 (1.86)
7.88 (1.92)
-0.09
...median [IQR]
6.60 [5.90, 7.80]
6.60 [5.90, 8.00]
0.00
7.57 [6.70, 9.20]
7.60 [6.80, 9.42]
-0.02
7.19 (1.86)
7.29 (1.92)
-0.05
...Missing; n (%)
28,897 (88.8%)
6,208 (90.3%)
-0.05
50,361 (99.1%)
15,069 (99.2%)
-0.01
79,258 (95.1%)
21,277 (96.5%)
-0.07
Lab result number- BNP mean 
                                      257                                          31 
                                           41                                               6 
0
0
...mean (sd)
286.40 (807.84)
181.63 (295.19)
0.17
462.66 (983.56)
98.17 (120.28)
0.52
393.81 (918.93)
124.17 (192.63)
0.41
...median [IQR]
100.00 [36.25, 
242.10]
66.10 [31.00, 
164.33]
0.06
159.00 [30.50, 
397.00]
55.00 [30.75, 161.50]
0.15
135.96 (918.93)
58.46 (192.63)
0.12
...Missing; n (%)
32,299 (99.2%)
6,841 (99.5%)
-0.04
50,754 (99.9%)
15,181 (100.0%)
-0.04
83,053 (99.6%)
22,022 (99.8%)
-0.04
Lab result number- BUN (mg/dl) mean 
                                  6,259                                   1,248 
                                        444                                         144 
0
0
...mean (sd)
18.65 (8.48)
17.48 (7.01)
0.15
333.36 (6,643.25)
1,684.66 (14,140.00)
-0.12
210.44 (5186.05)
1165.29 (11732.70)
-0.11
...median [IQR]
17.00 [14.00, 21.50] 16.00 [13.00, 20.00]
0.13
16.00 [13.50, 20.50]
16.33 [13.00, 21.00]
0.00
16.39 (5186.05)
16.23 (11732.70)
0.00
...Missing; n (%)
26,297 (80.8%)
5,624 (81.8%)
-0.03
50,351 (99.1%)
15,043 (99.1%)
0.00
76,648 (92.0%)
20,667 (93.7%)
-0.07
Lab result number- Creatinine (mg/dl) 
mean (only 0.1 to 15 included) 
                                  6,323                                   1,270 
                                        426                                         137 
0
0
...mean (sd)
1.09 (0.54)
1.04 (0.43)
0.10
1.04 (0.77)
1.06 (0.53)
-0.03
1.06 (0.69)
1.05 (0.50)
0.02
...median [IQR]
0.99 [0.84, 1.18]
0.98 [0.83, 1.14]
0.02
0.95 [0.82, 1.09]
1.00 [0.82, 1.19]
-0.08
0.97 (0.69)
0.99 (0.50)
-0.03
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)
26,233 (80.6%)
5,602 (81.5%)
-0.02
50,369 (99.2%)
15,050 (99.1%)
0.01
76,602 (91.9%)
20,652 (93.6%)
-0.07
Lab result number- HDL level (mg/dl) mean 
(only =<5000 included) 
                                  4,980                                   1,064 
                                        505                                         128 
0
0
...mean (sd)
46.47 (14.25)
44.40 (12.70)
0.15
40.89 (12.55)
41.43 (11.97)
-0.04
43.07 (13.24)
42.36 (12.20)
0.06
...median [IQR]
44.00 [37.00, 54.00] 43.00 [36.00, 51.00]
0.07
39.50 [34.00, 47.00]
40.00 [33.00, 47.00]
-0.04
41.26 (13.24)
40.93 (12.20)
0.03
...Missing; n (%)
27,576 (84.7%)
5,808 (84.5%)
0.01
50,290 (99.0%)
15,059 (99.2%)
-0.02
77,866 (93.4%)
20,867 (94.6%)
-0.05
Lab result number- LDL level (mg/dl) mean 
(only =<5000 included) 
                                  4,959                                   1,056 
                                        493                                         120 
0
0
...mean (sd)
105.33 (44.86)
108.39 (47.33)
-0.07
97.96 (50.99)
99.60 (50.63)
-0.03
100.84 (48.69)
102.34 (49.63)
-0.03
...median [IQR]
104.00 [77.00, 
132.00]
109.75 [81.00, 
135.75]
-0.12
96.50 [69.00, 129.00]
100.00 [71.00, 
135.50]
-0.07
99.43 (48.69)
103.04 (49.63)
-0.07
...Missing; n (%)
27,597 (84.8%)
5,816 (84.6%)
0.01
50,302 (99.0%)
15,067 (99.2%)
-0.02
77,899 (93.5%)
20,883 (94.7%)
-0.05
Lab result number- Total cholesterol 
(mg/dl) mean (only =<5000 included) 
                                  5,021                                   1,066 
                                        508                                         129 
0
0
...mean (sd)
189.22 (50.40)
195.25 (47.32)
-0.12
188.61 (58.77)
191.70 (62.84)
-0.05
188.85 (55.65)
192.81 (58.45)
-0.07
...median [IQR]
184.00 [155.50, 
217.00]
192.00 [163.38, 
224.00]
-0.16
185.50 [152.00, 
223.00]
187.00 [148.50, 
223.00]
-0.02
184.91 (55.65)
188.56 (58.45)
-0.06
...Missing; n (%)
27,535 (84.6%)
5,806 (84.5%)
0.00
50,287 (99.0%)
15,058 (99.2%)
-0.02
77,822 (93.4%)
20,864 (94.6%)
-0.05
Lab result number- Triglyceride level 
(mg/dl) mean (only =<5000 included) 
                                  4,939                                   1,070 
                                        496                                         127 
0
0
...mean (sd)
169.72 (134.74)
186.28 (155.47)
-0.11
211.56 (177.58)
215.24 (191.85)
-0.02
195.22 (162.20)
206.22 (181.30)
-0.06
...median [IQR]
138.50 [99.00, 
199.00]
150.00 [106.00, 
215.25]
-0.08
168.00 [116.00, 
243.12]
160.50 [110.00, 
229.00]
0.04
156.48 (162.20)
157.23 (181.30)
0.00
...Missing; n (%)
27,617 (84.8%)
5,802 (84.4%)
0.01
50,299 (99.0%)
15,060 (99.2%)
-0.02
77,916 (93.5%)
20,862 (94.6%)
-0.05
Lab result number- Hemoglobin mean 
(only >0 included)
                                  4,722                                       930 
                                        321                                            90 
0
0
...mean (sd)
13.97 (1.77)
14.57 (1.65)
-0.35
443.73 (7,701.64)
14.32 (1.38)
0.08
275.87 (6012.28)
14.40 (1.47)
0.06
...median [IQR]
14.10 [12.90, 15.20] 14.70 [13.60, 15.70]
-0.35
13.80 [12.92, 15.20]
14.43 [13.67, 15.15]
0.00
13.92 (6012.28)
14.51 (1.47)
0.00
...Missing; n (%)
27,834 (85.5%)
5,942 (86.5%)
-0.03
50,474 (99.4%)
15,097 (99.4%)
0.00
78,308 (93.9%)
21,039 (95.4%)
-0.07
Lab result number- Serum sodium mean 
(only > 90 and < 190 included)
                                  6,132                                   1,249 
                                        425                                         138 
0
0
...mean (sd)
139.85 (2.82)
139.76 (2.52)
0.03
138.74 (2.71)
138.76 (2.93)
-0.01
139.17 (2.75)
139.07 (2.81)
0.04
...median [IQR]
140.00 [138.00, 
142.00]
140.00 [138.00, 
141.00]
0.00
139.00 [137.00, 
140.50]
139.00 [137.00, 
141.00]
0.00
139.39 (2.75)
139.31 (2.81)
0.03
...Missing; n (%)
26,424 (81.2%)
5,623 (81.8%)
-0.02
50,370 (99.2%)
15,049 (99.1%)
0.01
76,794 (92.1%)
20,672 (93.7%)
-0.06
Lab result number- Albumin mean (only >0 
and <=10 included)
                                  5,624                                   1,178 
                                        360                                         115 
0
0
...mean (sd)
4.20 (0.34)
4.29 (0.32)
-0.27
4.07 (0.63)
4.13 (0.53)
-0.10
4.12 (0.54)
4.18 (0.47)
-0.12
...median [IQR]
4.20 [4.00, 4.40]
4.30 [4.10, 4.50]
-0.30
4.15 [4.00, 4.40]
4.20 [4.00, 4.40]
-0.09
4.17 (0.54)
4.23 (0.47)
-0.12
...Missing; n (%)
26,932 (82.7%)
5,694 (82.9%)
-0.01
50,435 (99.3%)
15,072 (99.2%)
0.01
77,367 (92.8%)
20,766 (94.1%)
-0.05
Lab result number- Glucose (fasting or 
random) mean (only 10-1000 included)
                                  6,067                                   1,242 
                                        408                                         132 
0
0
...mean (sd)
124.84 (56.69)
120.87 (51.78)
0.07
168.32 (67.53)
165.62 (78.32)
0.04
151.34 (63.52)
151.68 (71.12)
-0.01
...median [IQR]
105.00 [93.00, 
135.00]
103.00 [92.50, 
130.00]
0.04
149.00 [119.00, 
202.50]
143.90 [111.00, 
189.50]
0.07
131.81 (63.52)
131.16 (71.12)
0.01
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)
26,489 (81.4%)
5,630 (81.9%)
-0.01
50,387 (99.2%)
15,055 (99.1%)
0.01
76,876 (92.2%)
20,685 (93.8%)
-0.06
Lab result number- Potassium mean (only 
1-7 included)
                                  6,316                                   1,277 
                                        437                                         141 
0
0
...mean (sd)
4.39 (0.45)
4.40 (0.42)
-0.02
4.30 (0.46)
4.32 (0.47)
-0.04
4.34 (0.46)
4.34 (0.46)
0.00
...median [IQR]
4.40 [4.10, 4.66]
4.40 [4.10, 4.70]
0.00
4.30 [4.00, 4.60]
4.30 [4.00, 4.65]
0.00
4.34 (0.46)
4.33 (0.46)
0.02
...Missing; n (%)
26,240 (80.6%)
5,595 (81.4%)
-0.02
50,358 (99.1%)
15,046 (99.1%)
0.00
76,598 (91.9%)
20,641 (93.6%)
-0.07
Comorbidity Scores
CCI (180 days)- ICD9 and ICD10 
...mean (sd)
2.89 (2.14)
2.20 (1.82)
0.35
1.95 (1.72)
1.61 (1.42)
0.22
2.32 (1.90)
1.79 (1.56)
0.30
...median [IQR]
2.00 [1.00, 4.00]
2.00 [1.00, 3.00]
0.00
1.00 [1.00, 3.00]
1.00 [1.00, 2.00]
0.00
1.39 (1.90)
1.31 (1.56)
0.05
Frailty Score (mean): Empirical Version 365 
days, 
...mean (sd)
0.19 (0.05)
0.17 (0.04)
0.44
0.17 (0.04)
0.16 (0.03)
0.28
0.18 (0.04)
0.16 (0.03)
0.57
...median [IQR]
0.18 [0.16, 0.21]
0.17 [0.15, 0.19]
0.22
0.17 [0.15, 0.19]
0.16 [0.14, 0.18]
0.28
0.17 (0.04)
0.16 (0.03)
0.28
Healthcare Utilization
Any hospitalization; n (%)
32,547 (100.0%)
6,871 (100.0%)
#DIV/0!
50,794 (100.0%)
15,186 (100.0%)
#DIV/0!
83,341 (100.0%)
22,057 (100.0%)
#DIV/0!
Any hospitalization during prior 31-180 
days; n (%)
1,329 (4.1%)
212 (3.1%)
0.05
1,545 (3.0%)
367 (2.4%)
0.04
2,874 (3.4%)
0,579 (2.6%)
0.05
Endocrinologist Visit; n (%)
1,341 (4.1%)
327 (4.8%)
-0.03
1,666 (3.3%)
558 (3.7%)
-0.02
3,007 (3.6%)
0,885 (4.0%)
-0.02
Endocrinologist Visit (30 days prior); n (%)
689 (2.1%)
175 (2.5%)
-0.03
891 (1.8%)
317 (2.1%)
-0.02
1,580 (1.9%)
0,492 (2.2%)
-0.02
Endocrinologist Visit (31 to 180 days 
prior); n (%)
852 (2.6%)
194 (2.8%)
-0.01
1,002 (2.0%)
339 (2.2%)
-0.01
1,854 (2.2%)
0,533 (2.4%)
-0.01
Internal medicine/family medicine visits; n 
(%)
25,743 (79.1%)
4,863 (70.8%)
0.19
32,636 (64.3%)
9,499 (62.5%)
0.04
58,379 (70.0%)
14,362 (65.1%)
0.10
Internal medicine/family medicine visits 
(30 days prior) ; n (%)
21,362 (65.6%)
3,940 (57.3%)
0.17
20,203 (39.8%)
5,719 (37.7%)
0.04
41,565 (49.9%)
9,659 (43.8%)
0.12
Internal medicine/family medicine visits 
(31 to 180 days prior) ; n (%)
17,880 (54.9%)
3,050 (44.4%)
0.21
26,087 (51.4%)
7,448 (49.0%)
0.05
43,967 (52.7%)
10,498 (47.6%)
0.10
Cardiologist visit; n (%)
31,306 (96.2%)
6,623 (96.4%)
-0.01
17,435 (34.3%)
5,005 (33.0%)
0.03
48,741 (58.5%)
11,628 (52.7%)
0.12
Number of Cardiologist visits (30 days 
prior); n (%)
31,169 (95.7%)
6,604 (96.1%)
-0.02
14,457 (28.5%)
4,266 (28.1%)
0.01
45,626 (54.7%)
10,870 (49.3%)
0.11
Number of Cardiologist visits (31 to 180 
days prior); n (%)
5,961 (18.3%)
919 (13.4%)
0.13
5,678 (11.2%)
1,313 (8.6%)
0.09
11,639 (14.0%)
2,232 (10.1%)
0.12
Electrocardiogram ; n (%)
30,299 (93.1%)
6,341 (92.3%)
0.03
29,074 (57.2%)
8,281 (54.5%)
0.05
59,373 (71.2%)
14,622 (66.3%)
0.11
Use of glucose test strips; n (%)
420 (1.3%)
70 (1.0%)
0.03
477 (0.9%)
157 (1.0%)
-0.01
0,897 (1.1%)
0,227 (1.0%)
0.01
Dialysis; n (%)
164 (0.5%)
27 (0.4%)
0.01
188 (0.4%)
20 (0.1%)
0.06
352 (0.4%)
47 (0.2%)
0.04
number of different/distinct medication 
prescriptions
...mean (sd)
9.12 (4.59)
8.43 (4.41)
0.15
8.69 (4.31)
8.22 (4.10)
0.11
8.86 (4.42)
8.29 (4.20)
0.13
...median [IQR]
8.00 [6.00, 12.00]
7.00 [5.00, 11.00]
0.22
8.00 [5.00, 11.00]
7.00 [5.00, 10.00]
0.24
8.00 (4.42)
7.00 (4.20)
0.23
Number of Hospitalizations
...mean (sd)
1.12 (0.38)
1.09 (0.31)
0.09
1.10 (0.33)
1.07 (0.28)
0.10
1.11 (0.35)
1.08 (0.29)
0.09
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 (0.35)
1.00 (0.29)
0.00
Number of hospital days
...mean (sd)
4.12 (3.05)
3.71 (2.07)
0.16
3.87 (2.26)
3.60 (1.70)
0.14
3.97 (2.60)
3.63 (1.82)
0.15
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 (2.60)
3.00 (1.82)
0.00
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Number of Emergency Department (ED) 
visits 
...mean (sd)
1.07 (1.31)
0.88 (1.12)
0.16
3.06 (5.31)
3.09 (5.66)
-0.01
2.28 (4.23)
2.40 (4.74)
-0.03
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.00
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.00
1.61 (4.23)
1.69 (4.74)
-0.02
Number of Office visits
...mean (sd)
3.42 (3.55)
2.95 (3.26)
0.14
3.00 (3.50)
2.64 (3.14)
0.11
3.16 (3.52)
2.74 (3.18)
0.13
...median [IQR]
2.00 [1.00, 5.00]
2.00 [1.00, 4.00]
0.00
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.00
2.00 (3.52)
2.00 (3.18)
0.00
Number of Endocrinologist visits
...mean (sd)
0.17 (1.23)
0.19 (1.29)
-0.02
0.14 (1.13)
0.18 (1.30)
-0.03
0.50 (1.20)
0.40 (1.25)
0.08
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.39 (1.20)
0.31 (1.25)
0.07
Number of internal medicine/family 
medicine visits
...mean (sd)
7.06 (10.34)
5.39 (9.08)
0.17
3.96 (6.97)
3.52 (6.05)
0.07
5.17 (8.45)
4.10 (7.13)
0.14
...median [IQR]
4.00 [1.00, 9.00]
3.00 [0.00, 7.00]
0.10
2.00 [0.00, 5.00]
2.00 [0.00, 5.00]
0.00
2.78 (8.45)
2.31 (7.13)
0.06
Number of Cardiologist visits
...mean (sd)
9.87 (6.11)
9.28 (5.43)
0.10
1.18 (2.77)
1.04 (2.36)
0.05
4.57 (4.39)
3.61 (3.61)
0.24
...median [IQR]
9.00 [6.00, 13.00]
8.00 [6.00, 12.00]
0.17
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
3.52 (4.39)
2.49 (3.61)
0.26
Number electrocardiograms received 
...mean (sd)
3.53 (2.68)
3.19 (2.39)
0.13
1.15 (1.49)
1.05 (1.41)
0.07
2.08 (2.04)
1.72 (1.77)
0.19
...median [IQR]
3.00 [2.00, 5.00]
3.00 [1.00, 4.00]
0.00
1.00 [0.00, 2.00]
1.00 [0.00, 2.00]
0.00
1.78 (2.04)
1.62 (1.77)
0.08
Number of HbA1c tests ordered
...mean (sd)
0.34 (0.67)
0.31 (0.64)
0.05
0.21 (0.53)
0.23 (0.55)
-0.04
0.26 (0.59)
0.25 (0.58)
0.02
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.59)
0.00 (0.58)
0.00
Number of glucose tests ordered
...mean (sd)
0.17 (0.86)
0.15 (1.08)
0.02
0.12 (0.71)
0.12 (0.59)
0.00
0.14 (0.77)
0.13 (0.78)
0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.77)
0.00 (0.78)
0.00
Number of lipid tests ordered
...mean (sd)
0.50 (0.77)
0.49 (0.76)
0.01
0.37 (0.77)
0.43 (0.75)
-0.08
0.42 (0.77)
0.45 (0.75)
-0.04
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (0.77)
0.00 (0.75)
0.00
Number of creatinine tests ordered
...mean (sd)
0.06 (0.32)
0.03 (0.24)
0.11
0.06 (0.37)
0.04 (0.34)
0.06
0.06 (0.35)
0.04 (0.31)
0.06
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.35)
0.00 (0.31)
0.00
Number of BUN tests ordered
...mean (sd)
0.03 (0.30)
0.02 (0.38)
0.03
0.04 (0.36)
0.03 (0.25)
0.03
0.04 (0.34)
0.03 (0.30)
0.03
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.34)
0.00 (0.30)
0.00
Number of tests for microalbuminuria
...mean (sd)
0.19 (0.64)
0.17 (0.63)
0.03
0.10 (0.46)
0.12 (0.49)
-0.04
0.14 (0.54)
0.14 (0.54)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.54)
0.00 (0.54)
0.00
Total N distinct ICD9/ICD10 diagnoses at 
the 3rd digit level 
...mean (sd)
7.74 (9.49)
5.68 (8.22)
0.23
4.21 (7.22)
3.52 (6.47)
0.10
5.59 (8.18)
4.19 (7.06)
0.18
...median [IQR]
5.00 [0.00, 13.00]
0.00 [0.00, 9.00]
0.56
0.00 [0.00, 7.00]
0.00 [0.00, 4.00]
0.00
1.95 (8.18)
0.00 (7.06)
0.26
For PS
Hemorrhagic stroke+Other 
cerebrovascular disease+Cerebrovascular 
procedure (for PS); n (%)
465 (1.4%)
44 (0.6%)
0.08
420 (0.8%)
47 (0.3%)
0.07
885 (1.1%)
91 (0.4%)
0.08
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of creatinine tests ordered (for 
PS); n (%)
1,365 (4.2%)
160 (2.3%)
0.11
2,291 (4.5%)
467 (3.1%)
0.07
3,656 (4.4%)
0,627 (2.8%)
0.09
Occurrence of BUN tests ordered (for PS); n 
(%)
761 (2.3%)
85 (1.2%)
0.08
1,388 (2.7%)
311 (2.0%)
0.05
2,149 (2.6%)
0,396 (1.8%)
0.05
Occurrence of chronic renal insufficiency 
w/o CKD (for PS) ; n (%)
2,591 (8.0%)
320 (4.7%)
0.14
1,642 (3.2%)
301 (2.0%)
0.08
4,233 (5.1%)
0,621 (2.8%)
0.12
Chronic kidney disease Stage 1-2 (for PS); n 
(%)
668 (2.1%)
86 (1.3%)
0.06
418 (0.8%)
101 (0.7%)
0.01
1086 (1.3%)
187 (0.8%)
0.05
Chronic kidney disease Stage 3-6 (for PS); n 
(%)
3,066 (9.4%)
323 (4.7%)
0.18
2,086 (4.1%)
312 (2.1%)
0.12
5,152 (6.2%)
0,635 (2.9%)
0.16
Bladder stones+Kidney stones (for PS); n 
(%)
744 (2.3%)
148 (2.2%)
0.01
879 (1.7%)
263 (1.7%)
0.00
1,623 (1.9%)
0,411 (1.9%)
0.00
Diabetes with peripheral circulatory 
disorders+Gangrene+Osteomyelitis(for PS)  
with ICD10 ; n (%)
1,023 (3.1%)
115 (1.7%)
0.09
646 (1.3%)
144 (0.9%)
0.04
1,669 (2.0%)
0,259 (1.2%)
0.06
Alcohol abuse or dependence+Drug abuse 
or dependence (for PS); n (%)
11 (0.0%)
2 (0.0%)
#DIV/0!
505 (1.0%)
170 (1.1%)
-0.01
516 (0.6%)
172 (0.8%)
-0.02
Diabetes with other ophthalmic 
manifestations+Retinal detachment, 
vitreous hemorrhage, vitrectomy+Retinal 
laser coagulation therapy (for PS); n (%)
138 (0.4%)
18 (0.3%)
0.02
511 (1.0%)
129 (0.8%)
0.02
0,649 (0.8%)
0,147 (0.7%)
0.01
Other atherosclerosis+Cardiac conduction 
disorders+Other CVD (for PS)  ; n (%)
14,046 (43.1%)
2,369 (34.5%)
0.18
15,374 (30.3%)
3,959 (26.1%)
0.09
29,420 (35.3%)
6,328 (28.7%)
0.14
Previous cardiac procedure (CABG or PTCA 
or Stent) + History of CABG or PTCA (for PS) 
; n (%)
32,053 (98.5%)
6,809 (99.1%)
-0.06
49,901 (98.2%)
14,978 (98.6%)
-0.03
81,954 (98.3%)
21,787 (98.8%)
-0.04
Hyperthyroidism + Hypothyroidism + 
Other disorders of thyroid gland (for PS); n 
(%)
4,843 (14.9%)
758 (11.0%)
0.12
4,841 (9.5%)
1,139 (7.5%)
0.07
9,684 (11.6%)
1,897 (8.6%)
0.10
Delirium + Psychosis (for PS); n (%)
215 (0.7%)
22 (0.3%)
0.06
162 (0.3%)
25 (0.2%)
0.02
377 (0.5%)
47 (0.2%)
0.05
Any use of Meglitinides (for PS); n (%)
63 (0.2%)
16 (0.2%)
0.00
146 (0.3%)
37 (0.2%)
0.02
209 (0.3%)
53 (0.2%)
0.02
Any use of AGIs (for PS); n (%)
21 (0.1%)
3 (0.0%)
0.04
36 (0.1%)
5 (0.0%)
0.04
29,420 (35.3%)
6,328 (28.7%)
0.14
CKD stage 3-6 + dialysis (for PS); n (%)
3,070 (9.4%)
324 (4.7%)
0.18
2,095 (4.1%)
314 (2.1%)
0.12
5,165 (6.2%)
0,638 (2.9%)
0.16
Use of thiazide; n (%)
2,836 (8.7%)
460 (6.7%)
0.08
3,685 (7.3%)
913 (6.0%)
0.05
73,405 (88.1%)
19,556 (88.7%)
-0.02
Use of beta blockers; n (%)
28,402 (87.2%)
5,986 (87.1%)
0.00
45,003 (88.6%)
13,570 (89.4%)
-0.03
17,365 (20.8%)
3,512 (15.9%)
0.13
Use of calcium channel blockers; n (%)
7,523 (23.1%)
1,165 (17.0%)
0.15
9,842 (19.4%)
2,347 (15.5%)
0.10
16,281 (19.5%)
4,174 (18.9%)
0.02
All antidiabetic medications except 
Insulin; n (%)
6,890 (21.2%)
1,389 (20.2%)
0.02
9,391 (18.5%)
2,785 (18.3%)
0.01
6,521 (7.8%)
1,373 (6.2%)
0.06
DM Medications - Insulin ; n (%)
2,879 (8.8%)
621 (9.0%)
-0.01
3,775 (7.4%)
1,127 (7.4%)
0.00
6,654 (8.0%)
1,748 (7.9%)
0.00
Use of Low Intensity Statins; n (%)
12,186 (37.4%)
2,249 (32.7%)
0.10
20,920 (41.2%)
5,246 (34.5%)
0.14
33106 (39.7%)
7,495 (34.0%)
0.12
Use of High Intensity Statins; n (%)
19,933 (61.2%)
4,628 (67.3%)
-0.13
28,101 (55.3%)
9,643 (63.5%)
-0.17
48034 (57.6%)
14,271 (64.7%)
-0.15
Malignant hypertension; n (%)
2,535 (7.8%)
300 (4.4%)
0.14
26,315 (51.8%)
7,468 (49.2%)
0.05
28850 (34.6%)
7,768 (35.2%)
-0.01
Cardiovascular stress test; n (%)
92 (0.3%)
7 (0.1%)
0.04
93 (0.2%)
21 (0.1%)
0.03
0,185 (0.2%)
28 (0.1%)
0.03
Echocardiogram; n (%)
22,726 (69.8%)
4,521 (65.8%)
0.09
31,917 (62.8%)
9,448 (62.2%)
0.01
54,643 (65.6%)
13969 (63.3%)
0.05
Number of BNP tests
...mean (sd)
0.09 (0.38)
0.06 (0.29)
0.09
0.11 (0.37)
0.12 (0.37)
-0.03
0.10 (0.37)
0.10 (0.35)
0.00
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.37)
0.00 (0.35)
0.00
Number of Cardiac biomarkers tests 
(tropnin, CK-MBs, Myoglobin, CPK)
...mean (sd)
0.54 (1.57)
0.41 (1.70)
0.08
0.73 (1.62)
0.80 (1.75)
-0.04
0.66 (1.60)
0.68 (1.73)
-0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (1.60)
0.00 (1.73)
0.00
Number of Ambulatory Blood pressure 
monitoring tests
...mean (sd)
0.00 (0.03)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.03)
0.00 (0.02)
0.00
N of days on antihypertensive medications 
during baseline
...mean (sd)
85.76 (79.72)
67.64 (76.90)
0.23
75.26 (78.87)
62.73 (75.55)
0.16
79.36 (79.20)
64.26 (75.97)
0.19
...median [IQR]
88.00 [1.00, 174.00]
7.00 [1.00, 161.00]
1.03
31.00 [1.00, 168.00]
2.00 [1.00, 153.00]
0.38
53.26 (79.20)
3.56 (75.97)
0.64
N of days in database anytime prior
...mean (sd)
1,683.97 (1,295.93)
1,631.68 (1,231.18)
0.04
1,749.68 (1,252.71)
1,712.87 (1,215.17)
0.03
1724.01 (1269.77)
1687.58 (1220.18)
0.03
...median [IQR]
1,324.00 [651.25, 
2,398.00]
1,300.50 [633.00, 
2,373.75]
0.02
1,412.00 [682.00, 
2,626.00]
1,374.00 [702.00, 
2,607.00]
0.03
1377.63 (1269.77)
1351.10 (1220.18)
0.02
Mean Copay for per prescription cost 
(charges in U.S. $) (180-1 day prior)
...mean (sd)
23.49 (30.72)
25.23 (27.71)
-0.06
19.47 (32.84)
19.60 (23.87)
0.00
21.04 (32.03)
21.35 (25.13)
-0.01
...median [IQR]
15.00 [6.31, 30.00]
18.00 [8.00, 33.46]
-0.10
13.45 [5.38, 25.57]
13.28 [5.00, 26.50]
0.01
14.06 (32.03)
14.75 (25.13)
-0.02
...Missing; n (%)
4,763 (14.6%)
1,189 (17.3%)
-0.07
8,729 (17.2%)
2,756 (18.1%)
-0.02
13,492 (16.2%)
3945 (17.9%)
-0.05
Colonos; n (%)
1,036 (3.2%)
221 (3.2%)
0.00
1,556 (3.1%)
476 (3.1%)
0.00
2,592 (3.1%)
697 (3.2%)
-0.01
Fecal occult blood (FOB) test; n (%)
892 (2.7%)
216 (3.1%)
-0.02
1,516 (3.0%)
405 (2.7%)
0.02
2,408 (2.9%)
621 (2.8%)
0.01
Flu vaccine; n (%)
4,380 (13.5%)
793 (11.5%)
0.06
4,052 (8.0%)
1,152 (7.6%)
0.01
8,432 (10.1%)
1945 (8.8%)
0.04
Mammogram; n (%)
1,884 (5.8%)
312 (4.5%)
0.06
2,318 (4.6%)
545 (3.6%)
0.05
4,202 (5.0%)
857 (3.9%)
0.05
Pap smear; n (%)
580 (1.8%)
141 (2.1%)
-0.02
1,171 (2.3%)
348 (2.3%)
0.00
1,751 (2.1%)
489 (2.2%)
-0.01
Pneumonia vaccine; n (%)
3,945 (12.1%)
725 (10.6%)
0.05
2,330 (4.6%)
656 (4.3%)
0.01
6,275 (7.5%)
1381 (6.3%)
0.05
PSA test or Prostate exam for DRE; n (%)
4,334 (13.3%)
1,050 (15.3%)
-0.06
5,608 (11.0%)
2,061 (13.6%)
-0.08
9,942 (11.9%)
3111 (14.1%)
-0.07
Bone mineral density; n (%)
686 (2.1%)
105 (1.5%)
0.05
594 (1.2%)
103 (0.7%)
0.05
1,280 (1.5%)
208 (0.9%)
0.06
Use of Sympatomimetic agents; n (%)
261 (0.8%)
72 (1.0%)
-0.02
542 (1.1%)
186 (1.2%)
-0.01
0,803 (1.0%)
258 (1.2%)
-0.02
Use of CNS stimulants; n (%)
101 (0.3%)
29 (0.4%)
-0.02
267 (0.5%)
76 (0.5%)
0.00
0,368 (0.4%)
105 (0.5%)
-0.01
Use of estrogens, progestins, androgens; n 
(%)
946 (2.9%)
268 (3.9%)
-0.06
2,000 (3.9%)
656 (4.3%)
-0.02
2,946 (3.5%)
924 (4.2%)
-0.04
Use of Angiogenesis inhibitors; n (%)
14 (0.0%)
0 (0.0%)
#DIV/0!
29 (0.1%)
2 (0.0%)
0.04
0,043 (0.1%)
2 (0.0%)
0.04
Use of Oral Immunosuppressants; n (%)
63 (0.2%)
6 (0.1%)
0.03
128 (0.3%)
29 (0.2%)
0.02
0,191 (0.2%)
35 (0.2%)
0.00
Use of fondaparinux or Bivalirudin; n (%)
11 (0.0%)
3 (0.0%)
#DIV/0!
20 (0.0%)
2 (0.0%)
#DIV/0!
0,031 (0.0%)
5 (0.0%)
#DIV/0!
Use of other direct thrombin inhibitors 
(lepirudin, desirudin, argatroban); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0 (0.0%)
#DIV/0!
Use of Prasugrel ON CED; n (%)
418 (1.3%)
82 (1.2%)
0.01
428 (0.8%)
123 (0.8%)
0.00
0,846 (1.0%)
205 (0.9%)
0.01
Use of Prasugrel 180 to 1 day prior; n (%)
417 (1.3%)
90 (1.3%)
0.00
423 (0.8%)
135 (0.9%)
-0.01
0,840 (1.0%)
225 (1.0%)
0.00
Duration of index hospitalization (i.e. 
anchor hospitalization LOS)
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...mean (sd)
3.61 (2.82)
3.37 (1.49)
0.11
3.58 (1.67)
3.38 (1.34)
0.13
3.59 (2.19)
3.38 (1.39)
0.11
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 (2.19)
3.00 (1.39)
0.00
Number of D-dimer tests
...mean (sd)
0.04 (0.21)
0.02 (0.17)
0.10
0.05 (0.24)
0.06 (0.26)
-0.04
0.05 (0.23)
0.05 (0.24)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.23)
0.00 (0.24)
0.00
Numbe of CRP, high-sensitivity CRP tests
...mean (sd)
0.05 (0.30)
0.04 (0.24)
0.04
0.04 (0.28)
0.04 (0.28)
0.00
0.04 (0.29)
0.04 (0.27)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.29)
0.00 (0.27)
0.00
Number of PT or aPTTt tests
...mean (sd)
0.46 (1.66)
0.21 (0.99)
0.18
0.47 (1.28)
0.43 (1.01)
0.03
0.47 (1.44)
0.36 (1.00)
0.09
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 1.00]
0.00
0.00 (1.44)
0.00 (1.00)
0.00
Number of Bleeding time tests
...mean (sd)
0.00 (0.02)
0.00 (0.01)
0.00
0.00 (0.02)
0.00 (0.01)
0.00
0.00 (0.02)
0.00 (0.01)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.02)
0.00 (0.01)
0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 
days
...mean (sd)
3.74 (0.76)
3.42 (0.67)
0.45
3.38 (0.65)
3.16 (0.50)
0.38
3.52 (0.70)
3.24 (0.56)
0.44
...median [IQR]
4.00 [3.00, 4.00]
3.00 [3.00, 4.00]
1.40
3.00 [3.00, 4.00]
3.00 [3.00, 3.00]
0.00
3.39 (0.70)
3.00 (0.56)
0.62
Drug eluting stent; n (%)
14,767 (45.4%)
3,976 (57.9%)
-0.25
21,794 (42.9%)
7,216 (47.5%)
-0.09
36,561 (43.9%)
11192 (50.7%)
-0.14
Bare metal stent; n (%)
21,714 (66.7%)
4,304 (62.6%)
0.09
23,619 (46.5%)
7,240 (47.7%)
-0.02
45,333 (54.4%)
11544 (52.3%)
0.04
Use of CYP inhibitors; n (%)
5,868 (18.0%)
1,035 (15.1%)
0.08
8,155 (16.1%)
2,209 (14.5%)
0.04
14,023 (16.8%)
3244 (14.7%)
0.06
Use of CYP inducers; n (%)
237 (0.7%)
32 (0.5%)
0.03
363 (0.7%)
83 (0.5%)
0.03
0,600 (0.7%)
115 (0.5%)
0.03
Commercial vs Medicare Advantage- 
Business Type Code - CORRECT ONE - 
TRUVEN
...Commercial; n (%)
14,856 (45.6%)
4,721 (68.7%)
-0.48
15,837 (31.2%)
2,186 (14.4%)
0.41
30,693 (36.8%)
6907 (31.3%)
0.12
...Medicare Advantage; n (%)
17,700 (54.4%)
2,151 (31.3%)
0.48
34,958 (68.8%)
13,001 (85.6%)
-0.41
52,658 (63.2%)
15152 (68.7%)
-0.12
Commercial vs Medicare Advantage- 
Business Type Code
...COM = COMMERCIAL; n (%)
14,856 (45.6%)
4,721 (68.7%)
-0.48
-
-
#VALUE!
14,856 (45.6%)
4,721 (68.7%)
-0.48
...MCR = MEDICARE; n (%)
17,700 (54.4%)
2,151 (31.3%)
0.48
-
-
#VALUE!
17,700 (54.4%)
2,151 (31.3%)
0.48
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE (added 
in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- Data 
Type
...1 - Fee For Service; n (%)
-
-
#VALUE!
30,527 (60.1%)
11,547 (76.0%)
-0.35
30,527 (60.1%)
11,547 (76.0%)
-0.35
...2 - Encounter; n (%)
-
-
#VALUE!
4,431 (8.7%)
1,454 (9.6%)
-0.03
4,431 (8.7%)
1,454 (9.6%)
-0.03
...3 - Medicare; n (%)
-
-
#VALUE!
13,608 (26.8%)
1,922 (12.7%)
0.36
13,608 (26.8%)
1,922 (12.7%)
0.36
...4 - Medicare Encounter; n (%)
-
-
#VALUE!
2,229 (4.4%)
264 (1.7%)
0.16
2,229 (4.4%)
264 (1.7%)
0.16
Metropolitan Statistical Area - Urban (any 
MSA) vs Rural (non-MSA)
...Urban; n (%)
-
-
#VALUE!
38,125 (75.1%)
11,909 (78.4%)
-0.08
38,125 (75.1%)
11,909 (78.4%)
-0.08
...Rural; n (%)
-
-
#VALUE!
1,177 (2.3%)
269 (1.8%)
0.04
1,177 (2.3%)
269 (1.8%)
0.04
...Unknown/Missing; n (%)
-
-
#VALUE!
11,493 (22.6%)
3,009 (19.8%)
0.07
11,493 (22.6%)
3,009 (19.8%)
0.07
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

N of Generic name drugs
0
0
0
0
...mean (sd)
13.63 (11.66)
11.15 (10.53)
0.22
11.00 (9.22)
9.50 (8.53)
0.17
12.03 (10.24)
10.01 (9.20)
0.21
...median [IQR]
10.00 [5.00, 18.00]
8.00 [4.00, 15.00]
0.18
8.00 [5.00, 15.00]
7.00 [4.00, 12.00]
0.11
8.78 (10.24)
7.31 (9.20)
0.15
N of Brand name drugs
0
0
0
0
...mean (sd)
3.10 (4.35)
3.81 (4.42)
-0.16
3.61 (4.23)
3.98 (4.17)
-0.09
3.41 (4.28)
3.93 (4.25)
-0.12
...median [IQR]
2.00 [0.00, 4.00]
2.00 [1.00, 5.00]
0
2.00 [1.00, 5.00]
2.00 [2.00, 5.00]
0
2.00 (4.28)
2.00 (4.25)
0.00
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Variable
Clopidogrel 75mg
Prasugrel 10mg
St. Diff.
Clopidogrel 75mg
Prasugrel 10mg
St. Diff.
Clopidogrel 75mg
Ticagrelor 90mg
St. Diff.
Number of patients
                                 6,835                                  6,835 
                              15,097                               15,097 
                           21,932                            21,932 
Age
...mean (sd)
58.80 (11.42)
59.02 (10.25)
-0.02
55.93 (10.14)
56.12 (8.94)
-0.02
56.82 (10.56)
57.02 (9.37)
-0.02
...median [IQR]
58.00 [51.00, 67.00] 59.00 [52.00, 67.00]
-0.09
56.00 [49.00, 62.00] 57.00 [50.00, 62.00]
-0.10
56.62 (10.56)
57.62 (9.37)
-0.10
Age categories
...18 - 54; n (%)
2,525 (36.9%)
2,314 (33.9%)
0.06
6,689 (44.3%)
6,235 (41.3%)
0.06
9,214 (42.0%)
8,549 (39.0%)
0.06
...55 - 64; n (%)
2,191 (32.1%)
2,291 (33.5%)
-0.03
6,340 (42.0%)
6,718 (44.5%)
-0.05
8,531 (38.9%)
9,009 (41.1%)
-0.04
...65 - 74; n (%)
1,458 (21.3%)
1,861 (27.2%)
-0.14
1,285 (8.5%)
1,832 (12.1%)
-0.12
2,743 (12.5%)
3,693 (16.8%)
-0.12
...>= 75; n (%)
661 (9.7%)
369 (5.4%)
0.16
783 (5.2%)
312 (2.1%)
0.17
1,444 (6.6%)
0,681 (3.1%)
0.16
Gender- United
...Males; n (%)
5,252 (76.8%)
5,251 (76.8%)
0.00
12,060 (79.9%)
12,032 (79.7%)
0.00
17,312 (78.9%)
17,283 (78.8%)
0.00
...Females; n (%)
1,583 (23.2%)
1,584 (23.2%)
0.00
3,037 (20.1%)
3,065 (20.3%)
0.00
4,620 (21.1%)
4,649 (21.2%)
0.00
Region
...Northeast; n (%)
516 (7.5%)
519 (7.6%)
0.00
2,390 (15.8%)
2,403 (15.9%)
0.00
2,906 (13.3%)
2,922 (13.3%)
0.00
...South; n (%)
3,490 (51.1%)
3,498 (51.2%)
0.00
3,829 (25.4%)
3,783 (25.1%)
0.01
7,319 (33.4%)
7,281 (33.2%)
0.00
...Midwest; n (%)
1,676 (24.5%)
1,655 (24.2%)
0.01
6,469 (42.8%)
6,518 (43.2%)
-0.01
8,145 (37.1%)
8,173 (37.3%)
0.00
...West; n (%)
1,153 (16.9%)
1,163 (17.0%)
0.00
2,181 (14.4%)
2,174 (14.4%)
0.00
3,334 (15.2%)
3,337 (15.2%)
0.00
...Unknown+missing; n (%)
N/A
N/A
#VALUE!
228 (1.5%)
219 (1.5%)
0.00
228 (1.0%)
219 (1.0%)
0.00
CV Covariates
Ischemic heart disease; n (%)
6,835 (100.0%)
6,835 (100.0%)
#DIV/0!
15,097 (100.0%)
15,097 (100.0%)
#DIV/0!
21,932 (100.0%)
21,932 (100.0%)
#DIV/0!
Acute MI; n (%)
6,541 (95.7%)
6,548 (95.8%)
0.00
14,764 (97.8%)
14,756 (97.7%)
0.01
21305 (97.1%)
21304 (97.1%)
0.00
ACS/unstable angina; n (%)
2,496 (36.5%)
2,482 (36.3%)
0.00
4,708 (31.2%)
4,681 (31.0%)
0.00
7204 (32.8%)
7163 (32.7%)
0.00
Old MI; n (%)
711 (10.4%)
737 (10.8%)
-0.01
991 (6.6%)
1,009 (6.7%)
0.00
1702 (7.8%)
1746 (8.0%)
-0.01
Stable angina; n (%)
1,083 (15.8%)
1,064 (15.6%)
0.01
1,637 (10.8%)
1,655 (11.0%)
-0.01
2,720 (12.4%)
2,719 (12.4%)
0.00
Coronary atherosclerosis and other 
forms of chronic ischemic heart 
disease; n (%)
6,630 (97.0%)
6,627 (97.0%)
0.00
13,761 (91.2%)
13,777 (91.3%)
0.00
20,391 (93.0%)
20,404 (93.0%)
0.00
Other atherosclerosis with ICD10  ; n 
(%)
115 (1.7%)
96 (1.4%)
0.02
185 (1.2%)
156 (1.0%)
0.02
300 (1.4%)
252 (1.1%)
0.03
Previous cardiac procedure (CABG or 
PTCA or Stent) ; n (%)
6,755 (98.8%)
6,749 (98.7%)
0.01
14,848 (98.4%)
14,847 (98.3%)
0.01
21603 (98.5%)
21596 (98.5%)
0.00
History of CABG or PTCA; n (%)
1,761 (25.8%)
1,624 (23.8%)
0.05
2,106 (13.9%)
1,980 (13.1%)
0.02
3,867 (17.6%)
3,604 (16.4%)
0.03
Any stroke; n (%)
298 (4.4%)
287 (4.2%)
0.01
369 (2.4%)
390 (2.6%)
-0.01
0,667 (3.0%)
0,677 (3.1%)
-0.01
Ischemic stroke (w and w/o mention of 
cerebral infarction); n (%)
297 (4.3%)
287 (4.2%)
0.00
369 (2.4%)
390 (2.6%)
-0.01
0,666 (3.0%)
0,677 (3.1%)
-0.01
Hemorrhagic stroke; n (%)
1 (0.0%)
0 (0.0%)
#DIV/0!
1 (0.0%)
0 (0.0%)
#DIV/0!
2 (0.0%)
0 (0.0%)
#DIV/0!
TIA; n (%)
53 (0.8%)
46 (0.7%)
0.01
64 (0.4%)
63 (0.4%)
0.00
117 (0.5%)
109 (0.5%)
0.00
Other cerebrovascular disease; n (%)
48 (0.7%)
43 (0.6%)
0.01
39 (0.3%)
46 (0.3%)
0.00
87 (0.4%)
89 (0.4%)
0.00
Late effects of cerebrovascular disease; 
n (%)
29 (0.4%)
28 (0.4%)
0.00
20 (0.1%)
21 (0.1%)
0.00
49 (0.2%)
49 (0.2%)
0.00
Cerebrovascular procedure; n (%)
3 (0.0%)
1 (0.0%)
#DIV/0!
7 (0.0%)
1 (0.0%)
#DIV/0!
10 (0.0%)
2 (0.0%)
#DIV/0!
Heart failure (CHF); n (%)
917 (13.4%)
939 (13.7%)
-0.01
1,558 (10.3%)
1,623 (10.8%)
-0.02
2,475 (11.3%)
2,562 (11.7%)
-0.01
Peripheral Vascular Disease (PVD) or 
PVD Surgery ; n (%)
336 (4.9%)
359 (5.3%)
-0.02
410 (2.7%)
413 (2.7%)
0.00
0,746 (3.4%)
0,772 (3.5%)
-0.01
PS-matched
Truven
POOLED
Optum
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Atrial fibrillation; n (%)
404 (5.9%)
412 (6.0%)
0.00
543 (3.6%)
573 (3.8%)
-0.01
0,947 (4.3%)
0,985 (4.5%)
-0.01
Other cardiac dysrhythmia; n (%)
1,605 (23.5%)
1,626 (23.8%)
-0.01
2,685 (17.8%)
2,644 (17.5%)
0.01
4,290 (19.6%)
4,270 (19.5%)
0.00
Cardiac conduction disorders; n (%)
628 (9.2%)
638 (9.3%)
0.00
1,033 (6.8%)
957 (6.3%)
0.02
1661 (7.6%)
1595 (7.3%)
0.01
Other CVD; n (%)
1,884 (27.6%)
1,884 (27.6%)
0.00
3,058 (20.3%)
3,144 (20.8%)
-0.01
4,942 (22.5%)
5,028 (22.9%)
-0.01
Diabetes-related complications
Diabetic retinopathy; n (%)
125 (1.8%)
139 (2.0%)
-0.01
139 (0.9%)
152 (1.0%)
-0.01
0,264 (1.2%)
0,291 (1.3%)
-0.01
Diabetes with other ophthalmic 
manifestations; n (%)
0 (0.0%)
6 (0.1%)
-0.04
90 (0.6%)
108 (0.7%)
-0.01
0,090 (0.4%)
0,114 (0.5%)
-0.01
Retinal detachment, vitreous 
hemorrhage, vitrectomy; n (%)
4 (0.1%)
1 (0.0%)
0.04
3 (0.0%)
4 (0.0%)
#DIV/0!
7 (0.0%)
5 (0.0%)
#DIV/0!
Retinal laser coagulation therapy; n (%)
14 (0.2%)
11 (0.2%)
0.00
25 (0.2%)
28 (0.2%)
0.00
39 (0.2%)
39 (0.2%)
0.00
Occurrence of Diabetic Neuropathy  ; n 
(%)
355 (5.2%)
329 (4.8%)
0.02
326 (2.2%)
351 (2.3%)
-0.01
0,681 (3.1%)
0,680 (3.1%)
0.00
Occurrence of diabetic nephropathy  
with ICD10 ; n (%)
231 (3.4%)
237 (3.5%)
-0.01
196 (1.3%)
199 (1.3%)
0.00
0,427 (1.9%)
0,436 (2.0%)
-0.01
Hypoglycemia ; n (%)
66 (1.0%)
70 (1.0%)
0.00
129 (0.9%)
137 (0.9%)
0.00
0,195 (0.9%)
0,207 (0.9%)
0.00
Hyperglycemia; n (%)
537 (7.9%)
517 (7.6%)
0.01
693 (4.6%)
692 (4.6%)
0.00
1,230 (5.6%)
1,209 (5.5%)
0.00
Disorders of fluid electrolyte and acid-
base balance; n (%)
797 (11.7%)
802 (11.7%)
0.00
1,038 (6.9%)
1,067 (7.1%)
-0.01
1,835 (8.4%)
1,869 (8.5%)
0.00
Diabetic ketoacidosis; n (%)
32 (0.5%)
21 (0.3%)
0.03
46 (0.3%)
53 (0.4%)
-0.02
78 (0.4%)
74 (0.3%)
0.02
Hyperosmolar hyperglycemic 
nonketotic syndrome (HONK); n (%)
16 (0.2%)
18 (0.3%)
-0.02
13 (0.1%)
14 (0.1%)
0.00
29 (0.1%)
32 (0.1%)
0.00
Diabetes with peripheral circulatory 
disorders with ICD-10  ; n (%)
114 (1.7%)
101 (1.5%)
0.02
111 (0.7%)
124 (0.8%)
-0.01
0,225 (1.0%)
0,225 (1.0%)
0.00
Diabetic Foot; n (%)
59 (0.9%)
54 (0.8%)
0.01
103 (0.7%)
91 (0.6%)
0.01
162 (0.7%)
145 (0.7%)
0.00
Gangrene ; n (%)
6 (0.1%)
4 (0.1%)
0.00
5 (0.0%)
9 (0.1%)
-0.04
11 (0.1%)
13 (0.1%)
0.00
Lower extremity amputation; n (%)
16 (0.2%)
22 (0.3%)
-0.02
18 (0.1%)
23 (0.2%)
-0.03
34 (0.2%)
45 (0.2%)
0.00
Osteomyelitis; n (%)
17 (0.2%)
16 (0.2%)
0.00
36 (0.2%)
21 (0.1%)
0.03
53 (0.2%)
37 (0.2%)
0.00
Skin infections ; n (%)
200 (2.9%)
239 (3.5%)
-0.03
402 (2.7%)
436 (2.9%)
-0.01
0,602 (2.7%)
0,675 (3.1%)
-0.02
Erectile dysfunction; n (%)
217 (3.2%)
238 (3.5%)
-0.02
334 (2.2%)
326 (2.2%)
0.00
0,551 (2.5%)
0,564 (2.6%)
-0.01
Diabetes with unspecified 
complication; n (%)
138 (2.0%)
147 (2.2%)
-0.01
245 (1.6%)
244 (1.6%)
0.00
0,383 (1.7%)
0,391 (1.8%)
-0.01
Diabetes mellitus without mention of 
complications; n (%)
2,146 (31.4%)
2,128 (31.1%)
0.01
3,904 (25.9%)
3,932 (26.0%)
0.00
6,050 (27.6%)
6,060 (27.6%)
0.00
Hypertension: 1 inpatient or 2 
outpatient claims within 365 days; n 
(%)
4,975 (72.8%)
4,998 (73.1%)
-0.01
9,576 (63.4%)
9,586 (63.5%)
0.00
14,551 (66.3%)
14,584 (66.5%)
0.00
Hyperlipidemia ; n (%)
5,523 (80.8%)
5,550 (81.2%)
-0.01
9,909 (65.6%)
9,936 (65.8%)
0.00
15,432 (70.4%)
15,486 (70.6%)
0.00
Edema; n (%)
188 (2.8%)
182 (2.7%)
0.01
255 (1.7%)
260 (1.7%)
0.00
0,443 (2.0%)
0,442 (2.0%)
0.00
Renal Dysfunction (non-diabetic) ; n (%)
910 (13.3%)
933 (13.7%)
-0.01
1,193 (7.9%)
1,157 (7.7%)
0.01
2,103 (9.6%)
2,090 (9.5%)
0.00
Occurrence of acute renal disease ; n (%)
381 (5.6%)
403 (5.9%)
-0.01
474 (3.1%)
485 (3.2%)
-0.01
855 (3.9%)
888 (4.0%)
-0.01
Occurrence of chronic renal 
insufficiency; n (%)
523 (7.7%)
547 (8.0%)
-0.01
557 (3.7%)
553 (3.7%)
0.00
1,080 (4.9%)
1,100 (5.0%)
0.00
Chronic kidney disease ; n (%)
500 (7.3%)
524 (7.7%)
-0.02
533 (3.5%)
533 (3.5%)
0.00
1,033 (4.7%)
1,057 (4.8%)
0.00
CKD Stage 3-4; n (%)
287 (4.2%)
295 (4.3%)
0.00
257 (1.7%)
281 (1.9%)
-0.02
0,544 (2.5%)
0,576 (2.6%)
-0.01
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of hypertensive 
nephropathy; n (%)
397 (5.8%)
411 (6.0%)
-0.01
391 (2.6%)
410 (2.7%)
-0.01
788 (3.6%)
821 (3.7%)
-0.01
Occurrence of miscellaneous renal 
insufficiency ; n (%)
348 (5.1%)
358 (5.2%)
0.00
422 (2.8%)
412 (2.7%)
0.01
0,770 (3.5%)
0,770 (3.5%)
0.00
Glaucoma or cataracts ; n (%)
631 (9.2%)
573 (8.4%)
0.03
919 (6.1%)
896 (5.9%)
0.01
1,550 (7.1%)
1,469 (6.7%)
0.02
Cellulitis or abscess of toe; n (%)
36 (0.5%)
33 (0.5%)
0.00
41 (0.3%)
48 (0.3%)
0.00
77 (0.4%)
81 (0.4%)
0.00
Foot ulcer; n (%)
58 (0.8%)
52 (0.8%)
0.00
103 (0.7%)
91 (0.6%)
0.01
161 (0.7%)
143 (0.7%)
0.00
Bladder stones; n (%)
9 (0.1%)
7 (0.1%)
0.00
8 (0.1%)
8 (0.1%)
0.00
17 (0.1%)
15 (0.1%)
0.00
Kidney stones; n (%)
137 (2.0%)
143 (2.1%)
-0.01
271 (1.8%)
255 (1.7%)
0.01
0,408 (1.9%)
0,398 (1.8%)
0.01
Urinary tract infections (UTIs); n (%)
314 (4.6%)
303 (4.4%)
0.01
400 (2.6%)
439 (2.9%)
-0.02
0,714 (3.3%)
0,742 (3.4%)
-0.01
Dipstick urinalysis; n (%)
1,338 (19.6%)
1,363 (19.9%)
-0.01
3,037 (20.1%)
3,034 (20.1%)
0.00
4,375 (19.9%)
4,397 (20.0%)
0.00
Non-dipstick urinalysis; n (%)
653 (9.6%)
659 (9.6%)
0.00
1,171 (7.8%)
1,211 (8.0%)
-0.01
1,824 (8.3%)
1,870 (8.5%)
-0.01
Urine function test; n (%)
114 (1.7%)
105 (1.5%)
0.02
186 (1.2%)
189 (1.3%)
-0.01
0,300 (1.4%)
0,294 (1.3%)
0.01
Cytology; n (%)
50 (0.7%)
45 (0.7%)
0.00
98 (0.6%)
85 (0.6%)
0.00
148 (0.7%)
130 (0.6%)
0.01
Cystos; n (%)
66 (1.0%)
60 (0.9%)
0.01
121 (0.8%)
112 (0.7%)
0.01
187 (0.9%)
172 (0.8%)
0.01
Other Covariates
Liver disease; n (%)
4 (0.1%)
2 (0.0%)
0.04
6 (0.0%)
5 (0.0%)
#DIV/0!
0,010 (0.0%)
0,007 (0.0%)
#DIV/0!
Osteoarthritis; n (%)
790 (11.6%)
793 (11.6%)
0.00
1,138 (7.5%)
1,162 (7.7%)
-0.01
1,928 (8.8%)
1,955 (8.9%)
0.00
Other arthritis, arthropathies and 
musculoskeletal pain; n (%)
2,079 (30.4%)
2,059 (30.1%)
0.01
3,709 (24.6%)
3,698 (24.5%)
0.00
5,788 (26.4%)
5,757 (26.2%)
0.00
Dorsopathies; n (%)
1,460 (21.4%)
1,456 (21.3%)
0.00
2,421 (16.0%)
2,477 (16.4%)
-0.01
3,881 (17.7%)
3,933 (17.9%)
-0.01
Fractures; n (%)
110 (1.6%)
115 (1.7%)
-0.01
209 (1.4%)
208 (1.4%)
0.00
0,319 (1.5%)
0,323 (1.5%)
0.00
Falls ; n (%)
72 (1.1%)
85 (1.2%)
-0.01
53 (0.4%)
54 (0.4%)
0.00
125 (0.6%)
139 (0.6%)
0.00
Osteoporosis; n (%)
127 (1.9%)
137 (2.0%)
-0.01
141 (0.9%)
149 (1.0%)
-0.01
0,268 (1.2%)
0,286 (1.3%)
-0.01
Hyperthyroidism; n (%)
32 (0.5%)
34 (0.5%)
0.00
55 (0.4%)
37 (0.2%)
0.04
87 (0.4%)
71 (0.3%)
0.02
Hypothyroidism ; n (%)
653 (9.6%)
674 (9.9%)
-0.01
1,002 (6.6%)
986 (6.5%)
0.00
1,655 (7.5%)
1,660 (7.6%)
0.00
Other disorders of thyroid gland ; n (%)
136 (2.0%)
131 (1.9%)
0.01
208 (1.4%)
222 (1.5%)
-0.01
0,344 (1.6%)
0,353 (1.6%)
0.00
Depression; n (%)
635 (9.3%)
631 (9.2%)
0.00
899 (6.0%)
903 (6.0%)
0.00
1,534 (7.0%)
1,534 (7.0%)
0.00
Anxiety; n (%)
726 (10.6%)
716 (10.5%)
0.00
988 (6.5%)
993 (6.6%)
0.00
1,714 (7.8%)
1,709 (7.8%)
0.00
Sleep_Disorder; n (%)
566 (8.3%)
590 (8.6%)
-0.01
1,245 (8.2%)
1,207 (8.0%)
0.01
1,811 (8.3%)
1,797 (8.2%)
0.00
Dementia; n (%)
21 (0.3%)
22 (0.3%)
0.00
41 (0.3%)
38 (0.3%)
0.00
62 (0.3%)
60 (0.3%)
0.00
Delirium; n (%)
19 (0.3%)
20 (0.3%)
0.00
20 (0.1%)
23 (0.2%)
-0.03
39 (0.2%)
43 (0.2%)
0.00
Psychosis; n (%)
2 (0.0%)
2 (0.0%)
#DIV/0!
2 (0.0%)
2 (0.0%)
#DIV/0!
4 (0.0%)
4 (0.0%)
#DIV/0!
Obesity; n (%)
1,558 (22.8%)
1,593 (23.3%)
-0.01
2,340 (15.5%)
2,314 (15.3%)
0.01
3,898 (17.8%)
3,907 (17.8%)
0.00
Overweight; n (%)
239 (3.5%)
254 (3.7%)
-0.01
274 (1.8%)
257 (1.7%)
0.01
0,513 (2.3%)
0,511 (2.3%)
0.00
Smoking; n (%)
3,226 (47.2%)
3,191 (46.7%)
0.01
4,904 (32.5%)
4,789 (31.7%)
0.02
8,130 (37.1%)
7,980 (36.4%)
0.01
Alcohol abuse or dependence; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
176 (1.2%)
169 (1.1%)
0.01
176 (0.8%)
169 (0.8%)
0.00
Drug abuse or dependence; n (%)
1 (0.0%)
2 (0.0%)
#DIV/0!
1 (0.0%)
0 (0.0%)
#DIV/0!
2 (0.0%)
2 (0.0%)
#DIV/0!
COPD; n (%)
630 (9.2%)
673 (9.8%)
-0.02
953 (6.3%)
958 (6.3%)
0.00
1,583 (7.2%)
1,631 (7.4%)
-0.01
Asthma; n (%)
391 (5.7%)
397 (5.8%)
0.00
620 (4.1%)
616 (4.1%)
0.00
1,011 (4.6%)
1,013 (4.6%)
0.00
Obstructive sleep apnea; n (%)
645 (9.4%)
628 (9.2%)
0.01
1,057 (7.0%)
1,038 (6.9%)
0.00
1,702 (7.8%)
1,666 (7.6%)
0.01
Pneumonia; n (%)
210 (3.1%)
237 (3.5%)
-0.02
328 (2.2%)
357 (2.4%)
-0.01
0,538 (2.5%)
0,594 (2.7%)
-0.01
Imaging; n (%)
126 (1.8%)
132 (1.9%)
-0.01
137 (0.9%)
131 (0.9%)
0.00
263 (1.2%)
263 (1.2%)
0.00
Other Medications
Use of ACE inhibitors; n (%)
3,718 (54.4%)
3,724 (54.5%)
0.00
9,117 (60.4%)
9,031 (59.8%)
0.01
12,835 (58.5%)
12,755 (58.2%)
0.01
Use of ARBs; n (%)
1,134 (16.6%)
1,169 (17.1%)
-0.01
2,308 (15.3%)
2,326 (15.4%)
0.00
3,442 (15.7%)
3,495 (15.9%)
-0.01
Use of Loop Diuretics - United; n (%)
434 (6.3%)
448 (6.6%)
-0.01
690 (4.6%)
715 (4.7%)
0.00
1,124 (5.1%)
1,163 (5.3%)
-0.01
Use of other diuretics- United; n (%)
215 (3.1%)
249 (3.6%)
-0.03
488 (3.2%)
516 (3.4%)
-0.01
0,703 (3.2%)
0,765 (3.5%)
-0.02
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Use of nitrates-United; n (%)
3,016 (44.1%)
2,968 (43.4%)
0.01
6,873 (45.5%)
6,878 (45.6%)
0.00
9,889 (45.1%)
9,846 (44.9%)
0.00
Use of other hypertension drugs; n (%)
239 (3.5%)
270 (4.0%)
-0.03
514 (3.4%)
512 (3.4%)
0.00
0,753 (3.4%)
0,782 (3.6%)
-0.01
Use of digoxin- United; n (%)
58 (0.8%)
49 (0.7%)
0.01
95 (0.6%)
94 (0.6%)
0.00
153 (0.7%)
143 (0.7%)
0.00
Use of Anti-arrhythmics; n (%)
84 (1.2%)
88 (1.3%)
-0.01
178 (1.2%)
170 (1.1%)
0.01
262 (1.2%)
258 (1.2%)
0.00
Use of COPD/asthma meds- United; n 
(%)
737 (10.8%)
744 (10.9%)
0.00
1,626 (10.8%)
1,640 (10.9%)
0.00
2,363 (10.8%)
2,384 (10.9%)
0.00
Use of statins; n (%)
6,235 (91.2%)
6,239 (91.3%)
0.00
13,750 (91.1%)
13,729 (90.9%)
0.01
19,985 (91.1%)
19,968 (91.0%)
0.00
Use of other lipid-lowering drugs; n (%)
578 (8.5%)
598 (8.7%)
-0.01
1,382 (9.2%)
1,425 (9.4%)
-0.01
1,960 (8.9%)
2,023 (9.2%)
-0.01
Use of oral anticoagulants (Dabigatran, 
Rivaroxaban, Apixaban, Warfarin); n (%)
167 (2.4%)
171 (2.5%)
-0.01
405 (2.7%)
393 (2.6%)
0.01
0,572 (2.6%)
0,564 (2.6%)
0.00
Use of heparin and other low-molecular 
weight heparins; n (%)
31 (0.5%)
29 (0.4%)
0.01
2 (0.0%)
2 (0.0%)
#DIV/0!
33 (0.2%)
31 (0.1%)
0.03
Use of NSAIDs; n (%)
868 (12.7%)
891 (13.0%)
-0.01
1,920 (12.7%)
1,952 (12.9%)
-0.01
2,788 (12.7%)
2,843 (13.0%)
-0.01
Use of oral corticosteroids; n (%)
936 (13.7%)
946 (13.8%)
0.00
1,934 (12.8%)
2,015 (13.3%)
-0.01
2,870 (13.1%)
2,961 (13.5%)
-0.01
Use of bisphosphonate (United); n (%)
45 (0.7%)
58 (0.8%)
-0.01
72 (0.5%)
82 (0.5%)
0.00
117 (0.5%)
140 (0.6%)
-0.01
Use of opioids- United; n (%)
1,585 (23.2%)
1,555 (22.8%)
0.01
3,186 (21.1%)
3,248 (21.5%)
-0.01
4,771 (21.8%)
4,803 (21.9%)
0.00
Use of antidepressants; n (%)
1,047 (15.3%)
1,049 (15.3%)
0.00
2,039 (13.5%)
2,076 (13.8%)
-0.01
3,086 (14.1%)
3,125 (14.2%)
0.00
Use of antipsychotics; n (%)
45 (0.7%)
44 (0.6%)
0.01
104 (0.7%)
107 (0.7%)
0.00
0,149 (0.7%)
0,151 (0.7%)
0.00
Use of anticonvulsants; n (%)
503 (7.4%)
494 (7.2%)
0.01
775 (5.1%)
783 (5.2%)
0.00
1,278 (5.8%)
1,277 (5.8%)
0.00
Use of lithium- United; n (%)
9 (0.1%)
7 (0.1%)
0.00
16 (0.1%)
17 (0.1%)
0.00
25 (0.1%)
24 (0.1%)
0.00
Use of Benzos- United; n (%)
646 (9.5%)
660 (9.7%)
-0.01
1,460 (9.7%)
1,411 (9.3%)
0.01
2,106 (9.6%)
2,071 (9.4%)
0.01
Use of anxiolytics/hypnotics- United; n 
(%)
334 (4.9%)
351 (5.1%)
-0.01
798 (5.3%)
809 (5.4%)
0.00
1,132 (5.2%)
1,160 (5.3%)
0.00
Use of dementia meds- United; n (%)
14 (0.2%)
14 (0.2%)
0.00
15 (0.1%)
13 (0.1%)
0.00
29 (0.1%)
27 (0.1%)
0.00
Use of antiparkinsonian meds- United; 
n (%)
60 (0.9%)
63 (0.9%)
0.00
122 (0.8%)
118 (0.8%)
0.00
0,182 (0.8%)
0,181 (0.8%)
0.00
Entresto (sacubitril/valsartan); n (%)
1 (0.0%)
2 (0.0%)
#DIV/0!
1 (0.0%)
2 (0.0%)
#DIV/0!
2 (0.0%)
4 (0.0%)
#DIV/0!
Labs
Lab values- HbA1c (%) ; n (%)
709 (10.4%)
663 (9.7%)
0.02
156 (1.0%)
129 (0.9%)
0.01
0,865 (3.9%)
0,792 (3.6%)
0.02
Lab values- HbA1c (%) (within 3 
months) ; n (%)
447 (6.5%)
413 (6.0%)
0.02
105 (0.7%)
78 (0.5%)
0.03
0,552 (2.5%)
0,491 (2.2%)
0.02
Lab values- HbA1c (%) (within 6 
months) ; n (%)
709 (10.4%)
663 (9.7%)
0.02
156 (1.0%)
129 (0.9%)
0.01
0,865 (3.9%)
0,792 (3.6%)
0.02
Lab values- BNP; n (%)
39 (0.6%)
31 (0.5%)
0.01
7 (0.0%)
6 (0.0%)
#DIV/0!
46 (0.2%)
37 (0.2%)
0.00
Lab values- BNP (within 3 months); n 
(%)
33 (0.5%)
26 (0.4%)
0.01
7 (0.0%)
5 (0.0%)
#DIV/0!
40 (0.2%)
31 (0.1%)
0.03
Lab values- BNP (within 6 months); n 
(%)
39 (0.6%)
31 (0.5%)
0.01
7 (0.0%)
6 (0.0%)
#DIV/0!
46 (0.2%)
37 (0.2%)
0.00
Lab values- BUN (mg/dl); n (%)
1,233 (18.0%)
1,236 (18.1%)
0.00
142 (0.9%)
143 (0.9%)
0.00
1,375 (6.3%)
1,379 (6.3%)
0.00
Lab values- BUN (mg/dl) (within 3 
months); n (%)
769 (11.3%)
749 (11.0%)
0.01
98 (0.6%)
94 (0.6%)
0.00
0,867 (4.0%)
0,843 (3.8%)
0.01
Lab values- BUN (mg/dl) (within 6 
months); n (%)
1,233 (18.0%)
1,236 (18.1%)
0.00
142 (0.9%)
143 (0.9%)
0.00
1,375 (6.3%)
1,379 (6.3%)
0.00
Lab values- Creatinine (mg/dl) ; n (%)
1,265 (18.5%)
1,267 (18.5%)
0.00
152 (1.0%)
152 (1.0%)
0.00
1,417 (6.5%)
1,419 (6.5%)
0.00
Lab values- Creatinine (mg/dl) (within 3 
months) ; n (%)
789 (11.5%)
769 (11.3%)
0.01
103 (0.7%)
99 (0.7%)
0.00
0,892 (4.1%)
0,868 (4.0%)
0.01
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Lab values- Creatinine (mg/dl) (within 6 
months) ; n (%)
1,265 (18.5%)
1,267 (18.5%)
0.00
152 (1.0%)
152 (1.0%)
0.00
1,417 (6.5%)
1,419 (6.5%)
0.00
Lab values- HDL level (mg/dl); n (%)
1,020 (14.9%)
1,056 (15.4%)
-0.01
154 (1.0%)
129 (0.9%)
0.01
1,174 (5.4%)
1,185 (5.4%)
0.00
Lab values- HDL level (mg/dl) (within 3 
months); n (%)
596 (8.7%)
620 (9.1%)
-0.01
100 (0.7%)
84 (0.6%)
0.01
0,696 (3.2%)
0,704 (3.2%)
0.00
Lab values- HDL level (mg/dl) (within 6 
months); n (%)
1,020 (14.9%)
1,056 (15.4%)
-0.01
154 (1.0%)
129 (0.9%)
0.01
1,174 (5.4%)
1,185 (5.4%)
0.00
Lab values- LDL level (mg/dl) ; n (%)
1,035 (15.1%)
1,065 (15.6%)
-0.01
163 (1.1%)
134 (0.9%)
0.02
1,198 (5.5%)
1,199 (5.5%)
0.00
Lab values- LDL level (mg/dl) (within 3 
months) ; n (%)
601 (8.8%)
622 (9.1%)
-0.01
109 (0.7%)
86 (0.6%)
0.01
0,710 (3.2%)
0,708 (3.2%)
0.00
Lab values- LDL level (mg/dl) (within 6 
months) ; n (%)
1,035 (15.1%)
1,065 (15.6%)
-0.01
163 (1.1%)
134 (0.9%)
0.02
1,198 (5.5%)
1,199 (5.5%)
0.00
Lab values- NT-proBNP; n (%)
6 (0.1%)
7 (0.1%)
0.00
1 (0.0%)
0 (0.0%)
#DIV/0!
7 (0.0%)
7 (0.0%)
#DIV/0!
Lab values- NT-proBNP (within 3 
months); n (%)
3 (0.0%)
6 (0.1%)
-0.04
1 (0.0%)
0 (0.0%)
#DIV/0!
4 (0.0%)
6 (0.0%)
#DIV/0!
Lab values- NT-proBNP (within 6 
months); n (%)
6 (0.1%)
7 (0.1%)
0.00
1 (0.0%)
0 (0.0%)
#DIV/0!
7 (0.0%)
7 (0.0%)
#DIV/0!
Lab values- Total cholesterol (mg/dl) ; n 
(%)
1,040 (15.2%)
1,059 (15.5%)
-0.01
158 (1.0%)
130 (0.9%)
0.01
1,198 (5.5%)
1,189 (5.4%)
0.00
Lab values- Total cholesterol (mg/dl) 
(within 3 months) ; n (%)
608 (8.9%)
617 (9.0%)
0.00
104 (0.7%)
84 (0.6%)
0.01
0,712 (3.2%)
0,701 (3.2%)
0.00
Lab values- Total cholesterol (mg/dl) 
(within 6 months) ; n (%)
1,040 (15.2%)
1,059 (15.5%)
-0.01
158 (1.0%)
130 (0.9%)
0.01
1,198 (5.5%)
1,189 (5.4%)
0.00
Lab values- Triglyceride level (mg/dl); n 
(%)
1,024 (15.0%)
1,061 (15.5%)
-0.01
149 (1.0%)
128 (0.8%)
0.02
1,173 (5.3%)
1,189 (5.4%)
0.00
Lab values- Triglyceride level (mg/dl) 
(within 3 months); n (%)
596 (8.7%)
619 (9.1%)
-0.01
96 (0.6%)
83 (0.5%)
0.01
0,692 (3.2%)
0,702 (3.2%)
0.00
Lab values- Triglyceride level (mg/dl) 
(within 6 months); n (%)
1,024 (15.0%)
1,061 (15.5%)
-0.01
149 (1.0%)
128 (0.8%)
0.02
1,173 (5.3%)
1,189 (5.4%)
0.00
Lab result number- HbA1c (%) mean 
(only 2 to 20 included) 
                                     705                                      659 
                                      134                                       117 
0
0
...mean (sd)
7.42 (1.91)
7.18 (1.76)
0.13
8.30 (1.99)
8.21 (1.99)
0.05
8.03 (1.97)
7.89 (1.92)
0.07
...median [IQR]
6.80 [6.00, 8.50]
6.60 [5.90, 8.00]
0.11
7.80 [6.70, 9.72]
7.60 [6.85, 9.45]
0.10
7.49 (1.97)
7.29 (1.92)
0.10
...Missing; n (%)
6,130 (89.7%)
6,176 (90.4%)
-0.02
14,963 (99.1%)
14,980 (99.2%)
-0.01
21,093 (96.2%)
21,156 (96.5%)
-0.02
Lab result number- BNP mean 
                                        39                                         31 
                                            7                                             6 
0
0
...mean (sd)
141.44 (237.21)
181.63 (295.19)
-0.15
149.07 (138.05)
98.17 (120.28)
0.39
146.69 (175.08)
124.18 (192.65)
0.12
...median [IQR]
41.00 [13.00, 
131.00]
66.10 [31.00, 
164.33]
-0.09
113.00 [42.50, 
178.00]
55.00 [30.75, 
161.50]
0.45
90.56 (175.08)
58.46 (192.65)
0.17
...Missing; n (%)
6,796 (99.4%)
6,804 (99.5%)
-0.01
15,090 (100.0%)
15,091 (100.0%)
#DIV/0!
21,886 (99.8%)
21,895 (99.8%)
0.00
Lab result number- BUN (mg/dl) mean 
                                 1,233                                  1,236 
                                      142                                       143 
0
0
...mean (sd)
16.90 (6.75)
17.50 (7.03)
-0.09
16.04 (4.95)
1,696.39 
(14,189.00)
-0.17
16.31 (5.57)
1173.17 
(11772.36)
-0.14
...median [IQR]
16.00 [13.00, 19.00] 16.00 [13.00, 20.00]
0.00
15.50 [13.00, 18.62] 16.50 [13.00, 21.00]
0.00
15.66 (5.57)
16.34 (11772.36)
0.00
...Missing; n (%)
5,602 (82.0%)
5,599 (81.9%)
0.00
14,955 (99.1%)
14,954 (99.1%)
0.00
20,557 (93.7%)
20,553 (93.7%)
0.00
Lab result number- Creatinine (mg/dl) 
mean (only 0.1 to 15 included) 
                                 1,250                                  1,258 
                                      145                                       136 
                              1,395                               1,394 
...mean (sd)
1.01 (0.33)
1.04 (0.43)
-0.08
0.97 (0.26)
1.06 (0.53)
-0.22
0.98 (0.28)
1.05 (0.50)
-0.17
...median [IQR]
0.96 [0.82, 1.12]
0.98 [0.83, 1.14]
-0.05
0.93 [0.83, 1.04]
1.00 [0.82, 1.19]
-0.17
0.94 (0.28)
0.99 (0.50)
-0.12
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)
5,585 (81.7%)
5,577 (81.6%)
0.00
14,952 (99.0%)
14,961 (99.1%)
-0.01
20,537 (93.6%)
20,538 (93.6%)
0.00
Lab result number- HDL level (mg/dl) 
mean (only =<5000 included) 
                                 1,020                                  1,056 
                                      154                                       127 
                              1,174                               1,183 
...mean (sd)
44.94 (13.33)
44.43 (12.73)
0.04
40.24 (12.24)
41.52 (11.98)
-0.11
41.70 (12.59)
42.43 (12.22)
-0.06
...median [IQR]
43.00 [36.00, 51.38] 43.00 [36.00, 51.00]
0.00
38.67 [32.00, 46.25] 40.00 [33.00, 47.00]
-0.11
40.02 (12.59)
40.93 (12.22)
-0.07
...Missing; n (%)
5,815 (85.1%)
5,779 (84.6%)
0.01
14,943 (99.0%)
14,970 (99.2%)
-0.02
20,758 (94.6%)
20,749 (94.6%)
0.00
Lab result number- LDL level (mg/dl) 
mean (only =<5000 included) 
                                 1,022                                  1,047 
                                      148                                       119 
                              1,170                               1,166 
...mean (sd)
109.40 (47.20)
108.64 (47.27)
0.02
101.12 (49.66)
99.27 (50.71)
0.04
103.70 (48.91)
102.19 (49.66)
0.03
...median [IQR]
107.00 [81.00, 
138.00]
110.00 [81.00, 
136.00]
-0.06
100.50 [74.00, 
134.00]
100.00 [71.00, 
134.00]
0.01
102.53 (48.91)
103.12 (49.66)
-0.01
...Missing; n (%)
5,813 (85.0%)
5,788 (84.7%)
0.01
14,949 (99.0%)
14,978 (99.2%)
-0.02
20,762 (94.7%)
20,766 (94.7%)
0.00
Lab result number- Total cholesterol 
(mg/dl) mean (only =<5000 included) 
                                 1,039                                  1,057 
                                      158                                       128 
                              1,197                               1,185 
...mean (sd)
195.21 (53.28)
195.39 (47.33)
0.00
192.59 (52.95)
191.62 (63.08)
0.02
193.41 (53.05)
192.79 (58.63)
0.01
...median [IQR]
190.00 [161.00, 
222.00]
192.00 [163.75, 
224.00]
-0.04
192.50 [154.00, 
224.25]
187.00 [148.25, 
223.00]
0.09
191.72 (53.05)
188.56 (58.63)
0.06
...Missing; n (%)
5,796 (84.8%)
5,778 (84.5%)
0.01
14,939 (99.0%)
14,969 (99.2%)
-0.02
20,735 (94.5%)
20,747 (94.6%)
0.00
Lab result number- Triglyceride level 
(mg/dl) mean (only =<5000 included) 
                                 1,023                                  1,061 
                                      149                                       126 
                              1,172                               1,187 
...mean (sd)
182.19 (149.91)
185.54 (154.25)
-0.02
219.48 (160.86)
215.70 (192.55)
0.02
207.86 (157.53)
206.30 (181.48)
0.01
...median [IQR]
147.00 [103.50, 
216.00]
149.00 [106.00, 
214.00]
-0.01
184.00 [127.50, 
248.00]
162.25 [110.00, 
232.00]
0.12
172.47 (157.53)
158.12 (181.48)
0.08
...Missing; n (%)
5,812 (85.0%)
5,774 (84.5%)
0.01
14,948 (99.0%)
14,971 (99.2%)
-0.02
20,760 (94.7%)
20,745 (94.6%)
0.00
Lab result number- Hemoglobin mean 
(only >0 included)
                                     920                                      921 
                                      100                                          89 
                              1,020                               1,010 
...mean (sd)
14.50 (1.64)
14.57 (1.65)
-0.04
1,394.12 
14.31 (1.39)
0.14
964.17 (11448.42)
14.39 (1.48)
0.12
...median [IQR]
14.70 [13.50, 15.60] 14.70 [13.60, 15.70]
0.00
14.35 [13.20, 15.40] 14.40 [13.65, 15.20]
0.00
14.46 (11448.42)
14.49 (1.48)
0.00
...Missing; n (%)
5,915 (86.5%)
5,914 (86.5%)
0.00
14,997 (99.3%)
15,008 (99.4%)
-0.01
20,912 (95.3%)
20,922 (95.4%)
0.00
Lab result number- Serum sodium 
mean (only > 90 and < 190 included)
                                 1,213                                  1,237 
                                      143                                       137 
                              1,356                               1,374 
...mean (sd)
139.71 (2.67)
139.76 (2.52)
-0.02
138.34 (2.60)
138.76 (2.94)
-0.15
138.77 (2.62)
139.07 (2.82)
-0.11
...median [IQR]
140.00 [138.00, 
141.00]
140.00 [138.00, 
141.00]
0.00
138.40 [137.00, 
140.00]
139.00 [137.00, 
141.00]
-0.22
138.90 (2.62)
139.31 (2.82)
-0.15
...Missing; n (%)
5,622 (82.3%)
5,598 (81.9%)
0.01
14,954 (99.1%)
14,960 (99.1%)
0.00
20,576 (93.8%)
20,558 (93.7%)
0.00
Lab result number- Albumin mean (only 
>0 and <=10 included)
                                 1,136                                  1,167 
                                      123                                       114 
                              1,259                               1,281 
...mean (sd)
4.29 (0.32)
4.28 (0.32)
0.03
4.18 (0.50)
4.13 (0.53)
0.10
4.21 (0.45)
4.18 (0.47)
0.07
...median [IQR]
4.30 [4.10, 4.50]
4.30 [4.10, 4.50]
0.00
4.20 [4.00, 4.40]
4.20 [4.00, 4.40]
0.00
4.23 (0.45)
4.23 (0.47)
0.00
...Missing; n (%)
5,699 (83.4%)
5,668 (82.9%)
0.01
14,974 (99.2%)
14,983 (99.2%)
0.00
20,673 (94.3%)
20,651 (94.2%)
0.00
Lab result number- Glucose (fasting or 
random) mean (only 10-1000 included)
                                 1,198                                  1,230 
                                      132                                       131 
                              1,330                               1,361 
...mean (sd)
128.66 (60.29)
120.80 (51.79)
0.14
171.15 (68.93)
165.87 (78.57)
0.07
157.91 (66.36)
151.82 (71.31)
0.09
...median [IQR]
105.00 [92.50, 
141.00]
103.00 [92.50, 
129.25]
0.04
149.00 [118.25, 
218.12]
144.00 [110.00, 
190.00]
0.07
135.29 (66.36)
131.22 (71.31)
0.06
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...Missing; n (%)
5,637 (82.5%)
5,605 (82.0%)
0.01
14,965 (99.1%)
14,966 (99.1%)
0.00
20,602 (93.9%)
20,571 (93.8%)
0.00
Lab result number- Potassium mean 
(only 1-7 included)
                                 1,240                                  1,265 
                                      141                                       140 
                              1,381                               1,405 
...mean (sd)
4.38 (0.42)
4.40 (0.42)
-0.05
4.30 (0.43)
4.31 (0.48)
-0.02
4.32 (0.43)
4.34 (0.46)
-0.04
...median [IQR]
4.40 [4.10, 4.60]
4.40 [4.10, 4.70]
0.00
4.30 [4.00, 4.59]
4.30 [4.00, 4.67]
0.00
4.33 (0.43)
4.33 (0.46)
0.00
...Missing; n (%)
5,595 (81.9%)
5,570 (81.5%)
0.01
14,956 (99.1%)
14,957 (99.1%)
0.00
20,551 (93.7%)
20,527 (93.6%)
0.00
Comorbidity Scores
CCI (180 days)- ICD9 and ICD10 
...mean (sd)
2.17 (1.78)
2.20 (1.82)
-0.02
1.60 (1.45)
1.61 (1.43)
-0.01
1.78 (1.56)
1.79 (1.56)
-0.01
...median [IQR]
2.00 [1.00, 3.00]
2.00 [1.00, 3.00]
0.00
1.00 [1.00, 2.00]
1.00 [1.00, 2.00]
0.00
1.31 (1.56)
1.31 (1.56)
0.00
Frailty Score (mean): Empirical Version 
365 days, 
...mean (sd)
0.17 (0.04)
0.17 (0.04)
0.00
0.16 (0.03)
0.16 (0.03)
0.00
0.16 (0.03)
0.16 (0.03)
0.00
...median [IQR]
0.17 [0.15, 0.19]
0.17 [0.15, 0.19]
0.00
0.16 [0.14, 0.18]
0.16 [0.14, 0.18]
0.00
0.16 (0.03)
0.16 (0.03)
0.00
Healthcare Utilization
Any hospitalization; n (%)
6,832 (100.0%)
6,834 (100.0%)
#DIV/0!
15,097 (100.0%)
15,096 (100.0%)
#DIV/0!
21,929 (100.0%)
21,930 (100.0%)
#DIV/0!
Any hospitalization during prior 31-
180 days; n (%)
178 (2.6%)
210 (3.1%)
-0.03
278 (1.8%)
351 (2.3%)
-0.04
0,456 (2.1%)
0,561 (2.6%)
-0.03
Endocrinologist Visit; n (%)
319 (4.7%)
323 (4.7%)
0.00
500 (3.3%)
556 (3.7%)
-0.02
0,819 (3.7%)
0,879 (4.0%)
-0.02
Endocrinologist Visit (30 days prior); n 
(%)
151 (2.2%)
173 (2.5%)
-0.02
275 (1.8%)
315 (2.1%)
-0.02
0,426 (1.9%)
0,488 (2.2%)
-0.02
Endocrinologist Visit (31 to 180 days 
prior); n (%)
221 (3.2%)
191 (2.8%)
0.02
287 (1.9%)
339 (2.2%)
-0.02
0,508 (2.3%)
0,530 (2.4%)
-0.01
Internal medicine/family medicine 
visits; n (%)
4,888 (71.5%)
4,835 (70.7%)
0.02
9,379 (62.1%)
9,434 (62.5%)
-0.01
14,267 (65.1%)
14,269 (65.1%)
0.00
Internal medicine/family medicine 
visits (30 days prior) ; n (%)
4,019 (58.8%)
3,918 (57.3%)
0.03
5,587 (37.0%)
5,685 (37.7%)
-0.01
9,606 (43.8%)
9,603 (43.8%)
0.00
Internal medicine/family medicine 
visits (31 to 180 days prior) ; n (%)
3,008 (44.0%)
3,037 (44.4%)
-0.01
7,347 (48.7%)
7,389 (48.9%)
0.00
10,355 (47.2%)
10,426 (47.5%)
-0.01
Cardiologist visit; n (%)
6,637 (97.1%)
6,586 (96.4%)
0.04
4,991 (33.1%)
4,966 (32.9%)
0.00
11,628 (53.0%)
11,552 (52.7%)
0.01
Number of Cardiologist visits (30 days 
prior); n (%)
6,615 (96.8%)
6,567 (96.1%)
0.04
4,217 (27.9%)
4,234 (28.0%)
0.00
10,832 (49.4%)
10,801 (49.2%)
0.00
Number of Cardiologist visits (31 to 
180 days prior); n (%)
951 (13.9%)
910 (13.3%)
0.02
1,343 (8.9%)
1,297 (8.6%)
0.01
2,294 (10.5%)
2,207 (10.1%)
0.01
Electrocardiogram ; n (%)
6,232 (91.2%)
6,308 (92.3%)
-0.04
8,331 (55.2%)
8,225 (54.5%)
0.01
14,563 (66.4%)
14,533 (66.3%)
0.00
Use of glucose test strips; n (%)
73 (1.1%)
67 (1.0%)
0.01
140 (0.9%)
157 (1.0%)
-0.01
0,213 (1.0%)
0,224 (1.0%)
0.00
Dialysis; n (%)
22 (0.3%)
27 (0.4%)
-0.02
31 (0.2%)
20 (0.1%)
0.03
53 (0.2%)
47 (0.2%)
0.00
number of different/distinct 
medication prescriptions
...mean (sd)
8.41 (4.29)
8.41 (4.40)
0.00
8.17 (4.00)
8.21 (4.09)
-0.01
8.24 (4.09)
8.27 (4.19)
-0.01
...median [IQR]
7.00 [5.00, 11.00]
7.00 [5.00, 11.00]
0.00
7.00 [5.00, 10.00]
7.00 [5.00, 10.00]
0.00
7.00 (4.09)
7.00 (4.19)
0.00
Number of Hospitalizations
...mean (sd)
1.08 (0.30)
1.09 (0.31)
-0.03
1.07 (0.27)
1.07 (0.28)
0.00
1.07 (0.28)
1.08 (0.29)
-0.04
...median [IQR]
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 [1.00, 1.00]
1.00 [1.00, 1.00]
0.00
1.00 (0.28)
1.00 (0.29)
0.00
Number of hospital days
...mean (sd)
3.68 (2.09)
3.71 (2.08)
-0.01
3.60 (2.07)
3.60 (1.70)
0.00
3.62 (2.08)
3.63 (1.83)
-0.01
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 (2.08)
3.00 (1.83)
0.00
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Number of Emergency Department (ED) 
visits 
...mean (sd)
0.90 (1.06)
0.88 (1.13)
0.02
3.16 (5.52)
3.10 (5.67)
0.01
2.46 (4.62)
2.41 (4.75)
0.01
...median [IQR]
1.00 [0.00, 1.00]
1.00 [0.00, 1.00]
0.00
2.00 [0.00, 4.00]
2.00 [0.00, 4.00]
0.00
1.69 (4.62)
1.69 (4.75)
0.00
Number of Office visits
...mean (sd)
2.95 (3.25)
2.94 (3.25)
0.00
2.59 (2.99)
2.64 (3.14)
-0.02
2.70 (3.07)
2.73 (3.17)
-0.01
...median [IQR]
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.00
2.00 [1.00, 4.00]
2.00 [1.00, 4.00]
0.00
2.00 (3.07)
2.00 (3.17)
0.00
Number of Endocrinologist visits
...mean (sd)
0.21 (1.56)
0.19 (1.21)
0.01
0.14 (1.09)
0.18 (1.30)
-0.03
0.38 (1.08)
0.40 (1.25)
-0.02
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.31 (1.08)
0.31 (1.25)
0.00
Number of internal medicine/family 
medicine visits
...mean (sd)
5.36 (9.27)
5.39 (9.09)
0.00
3.48 (6.29)
3.51 (6.05)
0.00
4.07 (7.35)
4.10 (7.14)
0.00
...median [IQR]
3.00 [0.00, 7.00]
3.00 [0.00, 7.00]
0.00
1.00 [0.00, 5.00]
2.00 [0.00, 5.00]
-0.16
1.62 (7.35)
2.31 (7.14)
-0.10
Number of Cardiologist visits
...mean (sd)
9.25 (5.74)
9.28 (5.43)
-0.01
1.02 (2.32)
1.03 (2.35)
0.00
3.58 (3.74)
3.60 (3.60)
-0.01
...median [IQR]
8.00 [6.00, 12.00]
8.00 [6.00, 12.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
2.49 (3.74)
2.49 (3.60)
0.00
Number electrocardiograms received 
...mean (sd)
3.18 (2.35)
3.19 (2.39)
0.00
1.05 (1.36)
1.05 (1.41)
0.00
1.71 (1.73)
1.72 (1.77)
-0.01
...median [IQR]
3.00 [1.00, 4.00]
3.00 [1.00, 4.00]
0.00
1.00 [0.00, 2.00]
1.00 [0.00, 2.00]
0.00
1.62 (1.73)
1.62 (1.77)
0.00
Number of HbA1c tests ordered
...mean (sd)
0.30 (0.64)
0.31 (0.63)
-0.02
0.23 (0.55)
0.23 (0.55)
0.00
0.25 (0.58)
0.25 (0.58)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.58)
0.00 (0.58)
0.00
Number of glucose tests ordered
...mean (sd)
0.13 (0.63)
0.15 (1.08)
-0.02
0.11 (0.51)
0.12 (0.59)
-0.02
0.12 (0.55)
0.13 (0.78)
-0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.55)
0.00 (0.78)
0.00
Number of lipid tests ordered
...mean (sd)
0.47 (0.75)
0.49 (0.76)
-0.03
0.42 (0.82)
0.42 (0.75)
0.00
0.44 (0.80)
0.44 (0.75)
0.00
...median [IQR]
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (0.80)
0.00 (0.75)
0.00
Number of creatinine tests ordered
...mean (sd)
0.03 (0.25)
0.03 (0.24)
0.00
0.05 (0.32)
0.04 (0.34)
0.03
0.04 (0.30)
0.04 (0.31)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.30)
0.00 (0.31)
0.00
Number of BUN tests ordered
...mean (sd)
0.02 (0.16)
0.02 (0.38)
0.00
0.03 (0.26)
0.03 (0.25)
0.00
0.03 (0.23)
0.03 (0.30)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.23)
0.00 (0.30)
0.00
Number of tests for microalbuminuria
...mean (sd)
0.16 (0.57)
0.17 (0.62)
-0.02
0.11 (0.48)
0.12 (0.49)
-0.02
0.13 (0.51)
0.14 (0.53)
-0.02
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.51)
0.00 (0.53)
0.00
Total N distinct ICD9/ICD10 diagnoses 
at the 3rd digit level 
...mean (sd)
5.70 (8.02)
5.68 (8.21)
0.00
3.49 (6.39)
3.53 (6.48)
-0.01
4.18 (6.94)
4.20 (7.06)
0.00
...median [IQR]
0.00 [0.00, 10.00]
0.00 [0.00, 9.00]
0.00
0.00 [0.00, 4.00]
0.00 [0.00, 4.00]
0.00
0.00 (6.94)
0.00 (7.06)
0.00
For PS
Hemorrhagic stroke+Other 
cerebrovascular 
disease+Cerebrovascular procedure (for 
PS); n (%)
52 (0.8%)
44 (0.6%)
0.02
47 (0.3%)
47 (0.3%)
0.00
99 (0.5%)
91 (0.4%)
0.01
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

Occurrence of creatinine tests ordered 
(for PS); n (%)
178 (2.6%)
160 (2.3%)
0.02
479 (3.2%)
466 (3.1%)
0.01
0,657 (3.0%)
0,626 (2.9%)
0.01
Occurrence of BUN tests ordered (for 
PS); n (%)
92 (1.3%)
85 (1.2%)
0.01
290 (1.9%)
310 (2.1%)
-0.01
0,382 (1.7%)
0,395 (1.8%)
-0.01
Occurrence of chronic renal 
insufficiency w/o CKD (for PS) ; n (%)
298 (4.4%)
320 (4.7%)
-0.01
304 (2.0%)
298 (2.0%)
0.00
0,602 (2.7%)
0,618 (2.8%)
-0.01
Chronic kidney disease Stage 1-2 (for 
PS); n (%)
83 (1.2%)
85 (1.2%)
0.00
104 (0.7%)
100 (0.7%)
0.00
187 (0.9%)
185 (0.8%)
0.01
Chronic kidney disease Stage 3-6 (for 
PS); n (%)
306 (4.5%)
322 (4.7%)
-0.01
298 (2.0%)
309 (2.0%)
0.00
0,604 (2.8%)
0,631 (2.9%)
-0.01
Bladder stones+Kidney stones (for PS); n 
(%)
140 (2.0%)
148 (2.2%)
-0.01
274 (1.8%)
260 (1.7%)
0.01
0,414 (1.9%)
0,408 (1.9%)
0.00
Diabetes with peripheral circulatory 
disorders+Gangrene+Osteomyelitis(for 
PS)  with ICD10 ; n (%)
124 (1.8%)
115 (1.7%)
0.01
146 (1.0%)
142 (0.9%)
0.01
0,270 (1.2%)
0,257 (1.2%)
0.00
Alcohol abuse or dependence+Drug 
abuse or dependence (for PS); n (%)
1 (0.0%)
2 (0.0%)
#DIV/0!
177 (1.2%)
169 (1.1%)
0.01
178 (0.8%)
171 (0.8%)
0.00
Diabetes with other ophthalmic 
manifestations+Retinal detachment, 
vitreous hemorrhage, 
vitrectomy+Retinal laser coagulation 
therapy (for PS); n (%)
17 (0.2%)
18 (0.3%)
-0.02
112 (0.7%)
128 (0.8%)
-0.01
0,129 (0.6%)
0,146 (0.7%)
-0.01
Other atherosclerosis+Cardiac 
conduction disorders+Other CVD (for 
PS)  ; n (%)
2,350 (34.4%)
2,362 (34.6%)
0.00
3,918 (26.0%)
3,941 (26.1%)
0.00
6,268 (28.6%)
6,303 (28.7%)
0.00
Previous cardiac procedure (CABG or 
PTCA or Stent) + History of CABG or 
PTCA (for PS) ; n (%)
6,773 (99.1%)
6,772 (99.1%)
0.00
14,900 (98.7%)
14,889 (98.6%)
0.01
21,673 (98.8%)
21,661 (98.8%)
0.00
Hyperthyroidism + Hypothyroidism + 
Other disorders of thyroid gland (for 
PS); n (%)
739 (10.8%)
750 (11.0%)
-0.01
1,153 (7.6%)
1,132 (7.5%)
0.00
1,892 (8.6%)
1,882 (8.6%)
0.00
Delirium + Psychosis (for PS); n (%)
20 (0.3%)
22 (0.3%)
0.00
22 (0.1%)
25 (0.2%)
-0.03
42 (0.2%)
47 (0.2%)
0.00
Any use of Meglitinides (for PS); n (%)
11 (0.2%)
16 (0.2%)
0.00
36 (0.2%)
37 (0.2%)
0.00
47 (0.2%)
53 (0.2%)
0.00
Any use of AGIs (for PS); n (%)
2 (0.0%)
3 (0.0%)
#DIV/0!
3,918 (26.0%)
3,941 (26.1%)
0.00
6,268 (28.6%)
6,303 (28.7%)
0.00
CKD stage 3-6 + dialysis (for PS); n (%)
308 (4.5%)
323 (4.7%)
-0.01
299 (2.0%)
311 (2.1%)
-0.01
0,607 (2.8%)
0,634 (2.9%)
-0.01
Use of thiazide; n (%)
490 (7.2%)
459 (6.7%)
0.02
896 (5.9%)
910 (6.0%)
0.00
19,435 (88.6%)
19,440 (88.6%)
0.00
Use of beta blockers; n (%)
5,945 (87.0%)
5,953 (87.1%)
0.00
13,490 (89.4%)
13,487 (89.3%)
0.00
3,472 (15.8%)
3,490 (15.9%)
0.00
Use of calcium channel blockers; n (%)
1,164 (17.0%)
1,160 (17.0%)
0.00
2,308 (15.3%)
2,330 (15.4%)
0.00
4,161 (19.0%)
4,142 (18.9%)
0.00
All antidiabetic medications except 
Insulin; n (%)
1,371 (20.1%)
1,377 (20.1%)
0.00
2,790 (18.5%)
2,765 (18.3%)
0.01
1,386 (6.3%)
1,369 (6.2%)
0.00
DM Medications - Insulin ; n (%)
615 (9.0%)
614 (9.0%)
0.00
1,082 (7.2%)
1,116 (7.4%)
-0.01
1,697 (7.7%)
1,730 (7.9%)
-0.01
Use of Low Intensity Statins; n (%)
2,279 (33.3%)
2,243 (32.8%)
0.01
5,230 (34.6%)
5,227 (34.6%)
0.00
7509 (34.2%)
7,470 (34.1%)
0.00
Use of High Intensity Statins; n (%)
4,447 (65.1%)
4,598 (67.3%)
-0.05
9,372 (62.1%)
9,575 (63.4%)
-0.03
13819 (63.0%)
14,173 (64.6%)
-0.03
Malignant hypertension; n (%)
296 (4.3%)
300 (4.4%)
0.00
7,481 (49.6%)
7,421 (49.2%)
0.01
7777 (35.5%)
7,721 (35.2%)
0.01
Cardiovascular stress test; n (%)
7 (0.1%)
7 (0.1%)
0.00
16 (0.1%)
21 (0.1%)
0.00
0,023 (0.1%)
28 (0.1%)
0.00
Echocardiogram; n (%)
4,528 (66.2%)
4,503 (65.9%)
0.01
9,338 (61.9%)
9,391 (62.2%)
-0.01
13,866 (63.2%)
13894 (63.4%)
0.00
Number of BNP tests
...mean (sd)
0.06 (0.32)
0.06 (0.29)
0.00
0.12 (0.37)
0.12 (0.37)
0.00
0.10 (0.36)
0.10 (0.35)
0.00
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.36)
0.00 (0.35)
0.00
Number of Cardiac biomarkers tests 
(tropnin, CK-MBs, Myoglobin, CPK)
...mean (sd)
0.41 (1.47)
0.42 (1.70)
-0.01
0.79 (1.65)
0.80 (1.74)
-0.01
0.67 (1.60)
0.68 (1.73)
-0.01
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 1.00]
0.00 [0.00, 1.00]
0.00
0.00 (1.60)
0.00 (1.73)
0.00
Number of Ambulatory Blood pressure 
monitoring tests
...mean (sd)
0.00 (0.02)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
0.00 (0.03)
0.00 (0.02)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.03)
0.00 (0.02)
0.00
N of days on antihypertensive 
medications during baseline
...mean (sd)
67.42 (76.28)
67.51 (76.88)
0.00
62.89 (75.36)
62.70 (75.54)
0.00
64.30 (75.65)
64.20 (75.96)
0.00
...median [IQR]
7.00 [1.00, 158.00]
7.00 [1.00, 161.00]
0.00
1.00 [1.00, 152.00]
2.00 [1.00, 153.00]
-0.01
2.87 (75.65)
3.56 (75.96)
-0.01
N of days in database anytime prior
...mean (sd)
1,616.01 (1,214.94) 1,629.92 (1,231.27)
-0.01
1,708.25 (1,223.37) 1,713.51 (1,215.39)
0.00
1679.50 (1220.75) 1687.46 (1220.36)
-0.01
...median [IQR]
1,302.00 [622.00, 
2,331.00]
1,298.00 [631.00, 
2,369.00]
0.00
1,365.00 [681.00, 
2,602.50]
1,375.00 [702.00, 
2,609.00]
-0.01
1345.37 (1220.75) 1351.00 (1220.36)
0.00
Mean Copay for per prescription cost 
(charges in U.S. $) (180-1 day prior)
...mean (sd)
24.78 (29.15)
25.15 (27.70)
-0.01
19.46 (24.18)
19.56 (23.85)
0.00
21.12 (25.83)
21.30 (25.11)
-0.01
...median [IQR]
17.32 [6.94, 33.33]
17.92 [8.00, 33.33]
-0.02
13.33 [4.62, 26.99]
13.25 [5.00, 26.42]
0.00
14.57 (25.83)
14.71 (25.11)
-0.01
...Missing; n (%)
1,195 (17.5%)
1,189 (17.4%)
0.00
2,793 (18.5%)
2,751 (18.2%)
0.01
3,988 (18.2%)
3940 (18.0%)
0.01
Colonos; n (%)
233 (3.4%)
218 (3.2%)
0.01
476 (3.2%)
473 (3.1%)
0.01
0,709 (3.2%)
691 (3.2%)
0.00
Fecal occult blood (FOB) test; n (%)
215 (3.1%)
216 (3.2%)
-0.01
432 (2.9%)
404 (2.7%)
0.01
0,647 (3.0%)
620 (2.8%)
0.01
Flu vaccine; n (%)
784 (11.5%)
787 (11.5%)
0.00
1,142 (7.6%)
1,140 (7.6%)
0.00
1,926 (8.8%)
1927 (8.8%)
0.00
Mammogram; n (%)
323 (4.7%)
309 (4.5%)
0.01
546 (3.6%)
540 (3.6%)
0.00
0,869 (4.0%)
849 (3.9%)
0.01
Pap smear; n (%)
141 (2.1%)
138 (2.0%)
0.01
362 (2.4%)
347 (2.3%)
0.01
0,503 (2.3%)
485 (2.2%)
0.01
Pneumonia vaccine; n (%)
716 (10.5%)
723 (10.6%)
0.00
678 (4.5%)
649 (4.3%)
0.01
1,394 (6.4%)
1372 (6.3%)
0.00
PSA test or Prostate exam for DRE; n (%)
1,042 (15.2%)
1,040 (15.2%)
0.00
2,105 (13.9%)
2,048 (13.6%)
0.01
3,147 (14.3%)
3088 (14.1%)
0.01
Bone mineral density; n (%)
107 (1.6%)
105 (1.5%)
0.01
119 (0.8%)
103 (0.7%)
0.01
0,226 (1.0%)
208 (0.9%)
0.01
Use of Sympatomimetic agents; n (%)
73 (1.1%)
70 (1.0%)
0.01
170 (1.1%)
183 (1.2%)
-0.01
0,243 (1.1%)
253 (1.2%)
-0.01
Use of CNS stimulants; n (%)
32 (0.5%)
29 (0.4%)
0.01
83 (0.5%)
76 (0.5%)
0.00
0,115 (0.5%)
105 (0.5%)
0.00
Use of estrogens, progestins, 
androgens; n (%)
274 (4.0%)
261 (3.8%)
0.01
634 (4.2%)
643 (4.3%)
0.00
0,908 (4.1%)
904 (4.1%)
0.00
Use of Angiogenesis inhibitors; n (%)
2 (0.0%)
0 (0.0%)
#DIV/0!
15 (0.1%)
2 (0.0%)
0.04
0,017 (0.1%)
2 (0.0%)
0.04
Use of Oral Immunosuppressants; n (%)
4 (0.1%)
6 (0.1%)
0.00
38 (0.3%)
29 (0.2%)
0.02
0,042 (0.2%)
35 (0.2%)
0.00
Use of fondaparinux or Bivalirudin; n 
(%)
0 (0.0%)
3 (0.0%)
#DIV/0!
7 (0.0%)
2 (0.0%)
#DIV/0!
0,007 (0.0%)
5 (0.0%)
#DIV/0!
Use of other direct thrombin inhibitors 
(lepirudin, desirudin, argatroban); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
0 (0.0%)
0 (0.0%)
#DIV/0!
0,000 (0.0%)
0 (0.0%)
#DIV/0!
Use of Prasugrel ON CED; n (%)
90 (1.3%)
82 (1.2%)
0.01
104 (0.7%)
122 (0.8%)
-0.01
0,194 (0.9%)
204 (0.9%)
0.00
Use of Prasugrel 180 to 1 day prior; n 
(%)
94 (1.4%)
90 (1.3%)
0.01
112 (0.7%)
134 (0.9%)
-0.02
0,206 (0.9%)
224 (1.0%)
-0.01
Duration of index hospitalization (i.e. 
anchor hospitalization LOS)
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

...mean (sd)
3.38 (1.65)
3.38 (1.50)
0.00
3.39 (1.39)
3.38 (1.34)
0.01
3.39 (1.48)
3.38 (1.39)
0.01
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 (1.48)
3.00 (1.39)
0.00
Number of D-dimer tests
...mean (sd)
0.02 (0.17)
0.02 (0.17)
0.00
0.06 (0.26)
0.06 (0.26)
0.00
0.05 (0.24)
0.05 (0.24)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.24)
0.00 (0.24)
0.00
Numbe of CRP, high-sensitivity CRP 
tests
...mean (sd)
0.04 (0.23)
0.04 (0.24)
0.00
0.04 (0.25)
0.04 (0.28)
0.00
0.04 (0.24)
0.04 (0.27)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.24)
0.00 (0.27)
0.00
Number of PT or aPTTt tests
...mean (sd)
0.22 (1.04)
0.22 (0.99)
0.00
0.43 (0.98)
0.43 (1.00)
0.00
0.36 (1.00)
0.36 (1.00)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (1.00)
0.00 (1.00)
0.00
Number of Bleeding time tests
...mean (sd)
0.00 (0.01)
0.00 (0.01)
0.00
0.00 (0.00)
0.00 (0.01)
0.00
0.00 (0.01)
0.00 (0.01)
0.00
...median [IQR]
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 [0.00, 0.00]
0.00 [0.00, 0.00]
0.00
0.00 (0.01)
0.00 (0.01)
0.00
HAS-BLED Score (ICD-9 and ICD-10), 
180 days
...mean (sd)
3.41 (0.67)
3.42 (0.67)
-0.01
3.16 (0.49)
3.16 (0.50)
0.00
3.24 (0.55)
3.24 (0.56)
0.00
...median [IQR]
3.00 [3.00, 4.00]
3.00 [3.00, 4.00]
0.00
3.00 [3.00, 3.00]
3.00 [3.00, 3.00]
0.00
3.00 (0.55)
3.00 (0.56)
0.00
Drug eluting stent; n (%)
3,921 (57.4%)
3,947 (57.7%)
-0.01
7,223 (47.8%)
7,159 (47.4%)
0.01
11,144 (50.8%)
11106 (50.6%)
0.00
Bare metal stent; n (%)
4,286 (62.7%)
4,285 (62.7%)
0.00
7,177 (47.5%)
7,200 (47.7%)
0.00
11,463 (52.3%)
11485 (52.4%)
0.00
Use of CYP inhibitors; n (%)
1,028 (15.0%)
1,027 (15.0%)
0.00
2,162 (14.3%)
2,184 (14.5%)
-0.01
3,190 (14.5%)
3211 (14.6%)
0.00
Use of CYP inducers; n (%)
27 (0.4%)
32 (0.5%)
-0.01
94 (0.6%)
83 (0.5%)
0.01
0,121 (0.6%)
115 (0.5%)
0.01
Commercial vs Medicare Advantage- 
Business Type Code - CORRECT ONE - 
TRUVEN
...Commercial; n (%)
4,740 (69.3%)
4,686 (68.6%)
0.02
2,090 (13.8%)
2,184 (14.5%)
-0.02
6,830 (31.1%)
6870 (31.3%)
0.00
...Medicare Advantage; n (%)
2,095 (30.7%)
2,149 (31.4%)
-0.02
13,007 (86.2%)
12,913 (85.5%)
0.02
15,102 (68.9%)
15062 (68.7%)
0.00
Commercial vs Medicare Advantage- 
Business Type Code
...COM = COMMERCIAL; n (%)
4,740 (69.3%)
4,686 (68.6%)
0.02
-
-
#VALUE!
4,740 (69.3%)
4,686 (68.6%)
0.02
...MCR = MEDICARE; n (%)
2,095 (30.7%)
2,149 (31.4%)
-0.02
-
-
#VALUE!
2,095 (30.7%)
2,149 (31.4%)
-0.02
...MCD = MEDICAID; n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...NONE = NO BUSINESS LINE CODE 
(added in 2015); n (%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
...UNK = UNKNOWN (added in 2015); n 
(%)
0 (0.0%)
0 (0.0%)
#DIV/0!
-
-
#VALUE!
0 (0.0%)
0 (0.0%)
#DIV/0!
Commercial vs Medicare Advantage- 
Data Type
...1 - Fee For Service; n (%)
-
-
#VALUE!
11,534 (76.4%)
11,465 (75.9%)
0.01
11,534 (76.4%)
11,465 (75.9%)
0.01
...2 - Encounter; n (%)
-
-
#VALUE!
1,473 (9.8%)
1,448 (9.6%)
0.01
1,473 (9.8%)
1,448 (9.6%)
0.01
...3 - Medicare; n (%)
-
-
#VALUE!
1,821 (12.1%)
1,920 (12.7%)
-0.02
1,821 (12.1%)
1,920 (12.7%)
-0.02
...4 - Medicare Encounter; n (%)
-
-
#VALUE!
269 (1.8%)
264 (1.7%)
0.01
269 (1.8%)
264 (1.7%)
0.01
Metropolitan Statistical Area - Urban 
(any MSA) vs Rural (non-MSA)
...Urban; n (%)
-
-
#VALUE!
11,804 (78.2%)
11,827 (78.3%)
0.00
11,804 (78.2%)
11,827 (78.3%)
0.00
...Rural; n (%)
-
-
#VALUE!
260 (1.7%)
269 (1.8%)
-0.01
260 (1.7%)
269 (1.8%)
-0.01
...Unknown/Missing; n (%)
-
-
#VALUE!
3,033 (20.1%)
3,001 (19.9%)
0.01
3,033 (20.1%)
3,001 (19.9%)
0.01
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg

N of Generic name drugs
...mean (sd)
11.18 (9.42)
11.14 (10.51)
0.00
9.48 (7.70)
9.50 (8.54)
-0.00246
10.01 (8.27)
10.01 (9.20)
0.00
...median [IQR]
8.00 [5.00, 15.00]
8.00 [4.00, 15.00]
0.00
7.00 [4.00, 12.00]
7.00 [4.00, 12.00]
0
7.31 (8.27)
7.31 (9.20)
0.00
N of Brand name drugs
...mean (sd)
3.70 (5.32)
3.73 (4.20)
-0.01
3.86 (4.85)
3.93 (3.99)
-0.02
3.81 (5.00)
3.87 (4.06)
0.05
...median [IQR]
2.00 [1.00, 5.00]
2.00 [1.00, 5.00]
0.00
2.00 [1.00, 5.00]
2.00 [2.00, 5.00]
0
2.00 (5.00)
2.00 (4.06)
0.05
Table 1: Prasugrel 10 mg vs Clopidogrel 75 mg